Precipio (PRPO) 10-Q 8 Aug 14 2014 Q2 Quarterly report Financial data

DOCUMENT_AND_ENTITY_INFORMATIO

DOCUMENT AND ENTITY INFORMATION	6 Months Ended
	Jun. 30, 2014	Aug. 05, 2014
Document and Entity Information [Abstract]	'	'
Entity Registrant Name	'TRANSGENOMIC INC	'
Entity Central Index Key	'0001043961	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Smaller Reporting Company	'
Document Type	'10-Q	'
Document Period End Date	30-Jun-14	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q2	'
Amendment Flag	'false	'
Entity Common Stock, Shares Outstanding	'	7,353,695

CONDENSED_CONSOLIDATED_BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (USD $)	Jun. 30, 2014		Dec. 31, 2013
In Thousands, unless otherwise specified
CURRENT ASSETS:	'		'
Cash and cash equivalents	$1,191		$1,626
Accounts receivable, net	7,298		5,314
Inventories, net	4,009		3,957
Other current assets	879		938
Total current assets	13,377		11,835
PROPERTY AND EQUIPMENT:	'		'
Equipment	11,376		11,255
Furniture, fixtures & leasehold improvements	3,876		3,874
Property, Plant and Equipment, Gross	15,252		15,129
Less: accumulated depreciation	-13,416		-13,126
Property, Plant and Equipment, Net	1,836		2,003
OTHER ASSETS:	'		'
Goodwill	6,918		6,918
Intangibles, net	8,665		9,195
Other assets	295		327
Assets	31,091		30,278
CURRENT LIABILITIES:	'		'
Current maturities of long-term debt	691		242
Accounts payable	3,537		2,860
Accrued compensation	1,213		1,330
Accrued expenses	2,040		2,037
Deferred revenue	1,212		1,088
Other liabilities	1,068		1,068
Total current liabilities	9,761		8,625
LONG TERM LIABILITIES:	'		'
Long-term debt, less current maturities	6,211		6,318
Common stock warrant liability	350		600
Accrued preferred stock dividend	2,521		1,986
Other long-term liabilities	1,897		1,303
Total liabilities	20,740		18,832
STOCKHOLDERS’ EQUITY:	'		'
Preferred stock, $0.01 par value, 15,000,000 shares authorized, 4,029,502 and 2,586,205 shares issued and outstanding, respectively	40		26
Common stock, $0.01 par value, 150,000,000 shares authorized, 7,353,695 and 7,353,695 shares issued and outstanding, respectively (1)	73	[1]	73	[1]
Additional paid-in capital (1)	186,920	[1]	179,459	[1]
Accumulated other comprehensive income	424		390
Accumulated deficit	-177,106		-168,502
Total stockholders’ equity	10,351		11,446
Liabilities and equity	$31,091		$30,278
[1]	The shares of common stock and additional paid-in capital for all periods presented reflect the one-for-twelve reverse stock split that took effect on January 27, 2014.

CONDENSED_CONSOLIDATED_BALANCE1

CONDENSED CONSOLIDATED BALANCE SHEETS PARENTHETICALS (USD $)	Jun. 30, 2014	Dec. 31, 2013
Statement of Financial Position [Abstract]	'	'
Common stock, par value (in dollars per share)	$0.01	$0.01
Common stock, shares authorized	150,000,000	150,000,000
Common stock, shares issued	7,353,695	7,353,695
Common stock, shares outstanding	7,353,695	7,353,695
Preferred stock, par value (in dollars per share)	$0.01	$0.01
Preferred stock, shares authorized	15,000,000	15,000,000
Preferred stock, shares issued	4,029,502	2,586,205
Preferred stock, shares outstanding	4,029,502	2,586,205

UNAUDITED_CONDENSED_CONSOLIDAT

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)	3 Months Ended				6 Months Ended
In Thousands, except Share data, unless otherwise specified	Jun. 30, 2014		Jun. 30, 2013		Jun. 30, 2014		Jun. 30, 2013
Income Statement [Abstract]	'		'		'		'
NET SALES	$6,764		$7,306		$13,015		$14,680
COST OF GOODS SOLD:	4,371		4,333		8,128		8,452
Gross profit	2,393		2,973		4,887		6,228
OPERATING EXPENSES:	'		'		'		'
Selling, general and administrative	5,563		4,982		10,851		11,294
Research and development	785		913		1,530		1,677
Operating Expenses	6,348		5,895		12,381		12,971
OTHER INCOME (EXPENSE):	'		'		'		'
Interest expense, net	-146		-151		-328		-304
Warrant revaluation	200		200		250		600
Other, net	0		0		0		53
Other Income (Expense)	54		49		-78		349
LOSS FROM OPERATIONS	-3,955		-2,922		-7,494		-6,743
LOSS BEFORE INCOME TAXES	-3,901		-2,873		-7,572		-6,394
INCOME TAX (BENEFIT) EXPENSE	-8		-6		497		60
NET LOSS	-3,893		-2,867		-8,069		-6,454
PREFERRED STOCK DIVIDENDS	-305		-181		-535		-362
NET LOSS AVAILABLE TO COMMON STOCKHOLDERS	($4,198)		($3,048)		($8,604)		($6,816)
BASIC AND DILUTED LOSS PER COMMON SHARE (1)	($0.57)	[1]	($0.41)	[1]	($1.17)		($0.95)
BASIC AND DILUTED WEIGHTED-AVERAGE SHARES OF COMMON STOCK OUTSTANDING (1)	7,353,695	[1]	7,353,810	[1]	7,353,695	[1]	7,178,028	[1]
[1]	Net loss per share and the number of shares used in the per share calculations for all periods presented reflect the one-for-twelve reverse stock split that took effect on January 27, 2014.

UNAUDITED_CONDENSED_CONSOLIDAT1

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS PARENTHETICALS	0 Months Ended
	Jan. 27, 2014
Income Statement [Abstract]	'
Stock split, conversion ratio	0.0833

UNAUDITED_CONDENSED_CONSOLIDAT2

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (USD $)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Statement of Comprehensive Income [Abstract]	'	'	'	'
Net loss	($3,893)	($2,867)	($8,069)	($6,454)
Other comprehensive income (loss) - foreign currency translation adjustment	22	0	34	-173
Comprehensive Loss	($3,871)	($2,867)	($8,035)	($6,627)

UNAUDITED_CONDENSED_CONSOLIDAT3

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (USD $)		Total	Preferred Stock	Common Stock (1)		Additional Paid-in Capital (1)		Accumulated Deficit	Accumulated Other Comprehensive Income
In Thousands, except Share data, unless otherwise specified
Balance at Dec. 31, 2012		$20,274	$26	'		'		'	$435
Balance, shares at Dec. 31, 2012		'	2,586,205	'		'		'	'
Increase (Decrease) in Stockholders' Equity		'	'	'		'		'	'
Net loss		-6,454	'	'		'		'	'
Foreign currency translation adjustment, net of tax		-173	'	'		'		'	-200
Balance at Jun. 30, 2013		'	'	'		'		'	'
Balance at Dec. 31, 2012		20,274	26	64	[1]	171,538	[1]	-151,789	435
Balance, shares at Dec. 31, 2012		'	2,586,205	5,970,478	[1]	'		'	'
Increase (Decrease) in Stockholders' Equity		'	'	'		'		'	'
Net loss		-15,987	'	'		'		-15,987	'
Foreign currency translation adjustment, net of tax		-45	'	'		'		'	-45
Stock-based compensation		360	'	'		360	[1]	'	'
Private Placement, net, shares	[1]	'	'	1,383,217		'		'	'
Private placement, net		7,570	'	14	[1]	7,556	[1]	'	'
Other, shares	[1]	'	'	0		'		'	'
Other		0	'	-5	[1]	5	[1]	'	'
Dividends on preferred stock		-726	'	'		'		-726	'
Balance at Dec. 31, 2013		11,446	26	73	[1]	179,459	[1]	-168,502	390
Balance, shares at Dec. 31, 2013	[1]	'	2,586,205	7,353,695		'		'	'
Increase (Decrease) in Stockholders' Equity		'	'	'		'		'	'
Net loss		-8,069	'	'		'		-8,069	'
Foreign currency translation adjustment, net of tax		34	'	'		'		'	34
Stock-based compensation		570	'	'		570	[1]	'	'
Preferred stock agreement, shares		'	1,443,297	'		'		'	'
Preferred stock agreement		6,905	14	'		6,891	[1]	'	'
Dividends on preferred stock		-535	'	'		'		-535	'
Balance at Jun. 30, 2014		$10,351	$40	$73	[1]	$186,920	[1]	($177,106)	$424
Balance, shares at Jun. 30, 2014		'	4,029,502	7,353,695	[1]	'		'	'
[1]	The common stock shares and additional paid-in capital for all periods presented reflect the one-for-twelve reverse stock split that took effect on January 27, 2014.

UNAUDITED_CONDENSED_CONSOLIDAT4

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY PARENTHETICALS	0 Months Ended
	Jan. 27, 2014
Statement of Stockholders' Equity [Abstract]	'
Stock split, conversion ratio	0.0833

UNAUDITED_CONDENSED_CONSOLIDAT5

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013
CASH FLOWS USED IN OPERATING ACTIVITIES:	'	'
Net Loss	($8,069)	($6,454)
Adjustments to reconcile net loss to net cash flows used in operating activities:	'	'
Depreciation and amortization	981	1,431
Stock-based compensation	637	162
Provision for losses on doubtful accounts	1,523	2,197
Provision for losses on inventory obsolescence	55	0
Warrant revaluation	-250	-600
Loss on sale of fixed assets	0	9
Gain on foreign currency settlement	0	-62
Deferred interest	145	0
Deferred tax provision	550	0
Changes in operating assets and liabilities:	'	'
Accounts receivable	-3,479	-2,225
Inventories	-88	576
Other current assets	5	-67
Accounts payable	667	-287
Accrued expenses and other liabilities	66	-367
Net cash flows used in operating activities	-7,257	-5,687
CASH FLOWS USED IN INVESTING ACTIVITIES:	'	'
Purchases of property and equipment	-110	-355
Acquisition	0	-849
Other assets	-62	-157
Net cash flows used in investing activities	-172	-1,361
CASH FLOWS PROVIDED BY (USED IN) FINANCING ACTIVITIES:	'	'
Principal payments on capital lease obligations	-82	-176
Issuance of preferred stock, net	6,906	0
Issuance of common stock, net	0	7,570
Payment of deferred financing costs	0	-238
Proceeds from borrowings	4,440	8,000
Principal payment on note payable	-4,283	-6,171
Net cash flows provided by financing activities	6,981	8,985
EFFECT OF FOREIGN CURRENCY EXCHANGE RATE CHANGES ON CASH	13	-46
NET CHANGE IN CASH AND CASH EQUIVALENTS	-435	1,891
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD	1,626	4,497
CASH AND CASH EQUIVALENTS AT END OF PERIOD	1,191	6,388
Cash paid during the period for:	'	'
Interest	147	460
SUPPLEMENTAL DISCLOSURE OF NON-CASH INFORMATION	'	'
Dividends accrued on preferred stock	535	363
Deferred financing costs in accounts payable	$0	$25

BUSINESS_DESCRIPTION

BUSINESS DESCRIPTION	6 Months Ended
	Jun. 30, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Business Description	'
	BUSINESS DESCRIPTION
	Business Description.
	Transgenomic, Inc. is a global biotechnology company advancing personalized medicine in the detection and treatment of cancer and inherited diseases through its proprietary molecular technologies and world-class clinical and research services. Our operations are organized and reviewed by management along our product lines and presented in the following two complementary business segments:
	•	Laboratory Services. Our laboratories specialize in genetic testing for cardiology, neurology, mitochondrial disorders and oncology. Our Patient Testing laboratories located in New Haven, Connecticut and Omaha, Nebraska are certified under the Clinical Laboratory Improvement Amendment as high complexity labs and our Omaha facility is also accredited by the College of American Pathologists. Our Biomarker Identification laboratory located in Omaha, Nebraska also provides pharmacogenomics research services supporting Phase II and Phase III clinical trials conducted by pharmaceutical companies. Our laboratories employ a variety of genomic testing service technologies, including ICE COLD-PCR technology. ICE COLD-PCR is a proprietary platform technology that can be run in any laboratory with standard PCR technology and that enables detection of multiple unknown mutations from virtually any sample type including tissue biopsies, blood, cell-free DNA (“cfDNA”) and circulating tumor cells at levels greater than 1,000-fold higher than standard DNA sequencing techniques.
	•	Genetic Assays and Platforms. Our proprietary product is the WAVE® System, which has broad applicability to genetic variation detection in both molecular genetic research and molecular diagnostics. We also distribute bioinstruments produced by other manufacturers (“OEM Equipment”) through our sales and distribution network. Service contracts to maintain installed systems are sold and supported by our technical support personnel. The installed WAVE base and some OEM Equipment platforms generate a demand for consumables that are required for the continued operation of the bioinstruments. We develop, manufacture and sell these consumable products. In addition, we manufacture and sell consumable products that can be used on multiple, independent platforms. These products include a range of chromatography columns.

SUMMARY_OF_SIGNIFICANT_ACCOUNT

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	6 Months Ended
	Jun. 30, 2014
Accounting Policies [Abstract]	'
Summary of Significant Accounting Policies	'
	SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
	Basis of Presentation.
	The condensed consolidated balance sheet as of December 31, 2013 was derived from our audited balance sheet as of that date. The accompanying condensed consolidated financial statements as of and for the three and six months ended June 30, 2014 and 2013 are unaudited and reflect all adjustments (consisting of only normal recurring adjustments) that are, in the opinion of management, necessary for a fair presentation of the financial position and operating results for the interim periods. These unaudited condensed consolidated financial statements and notes should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December 31, 2013 contained in our Annual Report on Form 10-K, filed with the Securities and Exchange Commission on March 27, 2014. The results of operations for the interim periods presented are not necessarily indicative of the results for the entire year.
	Following approval of our stockholders, on January 15, 2014, our Board of Directors approved a reverse split of our common stock, par value $0.01, at a ratio of one-for-twelve. This reverse stock split became effective on January 27, 2014 and, unless otherwise indicated, all share amounts, per share data, share prices, exercise prices and conversion rates set forth in these notes and the accompanying consolidated financial statements have, where applicable, been adjusted retroactively to reflect this reverse stock split.
	Principles of Consolidation.
	The consolidated financial statements include the accounts of Transgenomic, Inc. and our wholly owned subsidiary. All inter-company balances and transactions have been eliminated in consolidation.
	Risks and Uncertainties.
	Certain risks and uncertainties are inherent in our day-to-day operations and in the process of preparing our financial statements. The more significant of those risks are presented below and throughout the notes to the unaudited condensed consolidated financial statements.
	Use of Estimates.
	The preparation of condensed consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of net sales and expenses during the reporting period. In addition, estimates and assumptions associated with the determination of the fair value of certain assets and related impairments require considerable judgment by management. Actual results could differ from the estimates and assumptions used in preparing these consolidated financial statements.
	Reclassifications.
	Certain prior period amounts of selling, general and administrative expenses have been reclassified to cost of goods sold in order to conform to the current period presentation. These reclassifications had no effect on previously reported net earnings.
	Fair Value.
	Unless otherwise specified, book value approximates fair market value. The common stock warrant liability is recorded at fair value. See Note 9 - “Fair Value” to the notes to our accompanying unaudited condensed consolidated financial statements for additional information.
	Cash and Cash Equivalents.
	Cash and cash equivalents include cash and investments with original maturities at the date of acquisition of three months or less.
	Concentrations of Cash.
	From time to time, we may maintain a cash position with financial institutions in amounts that exceed federally insured limits. We have not experienced any losses on such accounts as of June 30, 2014.
	Accounts Receivable.
	The following is a summary of activity for the allowance for doubtful accounts during the three and six months ended June 30, 2014 and 2013:
		Dollars in Thousands
		Beginning		Provision		Write-Offs			Ending
		Balance							Balance
	Three Months Ended June 30, 2014	$	3,540	$	850	$	(349	)	$	4,041
	Three Months Ended June 30, 2013	$	2,549	$	608	$	(795	)	$	2,362
	Six Months Ended June 30, 2014	$	3,838	$	1,523	$	(1,320	)	$	4,041
	Six Months Ended June 30, 2013	$	2,171	$	2,197	$	(2,006	)	$	2,362
	While payment terms are generally 30 days, we have also provided extended payment terms in certain cases. In addition, we operate globally and the payment terms for some of our international customers may be greater than 90 days. Accounts receivable are carried at original invoice amount and shown net of allowance for doubtful accounts and contractual allowances. The estimate made for doubtful accounts is based on a review of all outstanding amounts on a quarterly basis. We determine the allowance for doubtful accounts by assigning a consistent reserve percentage to each accounts receivable aging category and contractual allowances by regularly evaluating individual customer payment history. Accounts receivable are written off when deemed uncollectible and all collection efforts have been exhausted. During the six months ended June 30, 2014, in accordance with our stated policy, we wrote-off approximately $1.3 million of accounts receivable, related to services rendered in prior year periods, determined to be uncollectible.
	Inventories.
	Inventories are stated at the lower of cost or market net of allowance for obsolete inventory. Cost is computed using standard costs for finished goods and average or latest actual cost for raw materials and work in process, which approximates the first-in, first-out (FIFO) method.
	The following is a summary of activity for the allowance for obsolete inventory during the three and six months ended June 30, 2014 and 2013:
		Dollars in Thousands
		Beginning		Provision		Write-Offs			Ending
		Balance							Balance
	Three Months Ended June 30, 2014	$	849	$	—	$	(6	)	$	843
	Three Months Ended June 30, 2013	$	611	$	—	$	(18	)	$	593
	Six Months Ended June 30, 2014	$	799	$	55	$	(11	)	$	843
	Six Months Ended June 30, 2013	$	616	$	—	$	(23	)	$	593
	We determine the allowance for obsolescence by evaluating inventory quarterly for items deemed to be slow moving or obsolete.
	Property and Equipment.
	Property and equipment are carried at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the related assets as follows:
	Leasehold improvements	1 to 10 years
	Furniture and fixtures	3 to 7 years
	Production equipment	3 to 7 years
	Computer equipment	3 to 7 years
	Research and development equipment	2 to 7 years
	Depreciation expense related to property and equipment was $0.1 million and $0.2 million for the three months ended June 30, 2014 and 2013, respectively. Included in depreciation for each of the three months ended June 30, 2014 and 2013 was $0.1 million related to equipment acquired under capital leases. Depreciation expense related to property and equipment was $0.2 million and $0.3 million for the six months ended June 30, 2014 and 2013, respectively. Included in depreciation for each of the six months ended June 30, 2014 and 2013 was $0.1 million related to equipment acquired under capital leases.
	Goodwill.
	Goodwill is tested for impairment annually. We perform this impairment analysis during the fourth quarter of each year or when a significant event occurs that may impact goodwill. Impairment occurs when the carrying value is determined to be not recoverable, thereby causing the carrying value of the goodwill to exceed its fair value. If impaired, the asset’s carrying value is reduced to its fair value. No events have transpired in the six months ended June 30, 2014 that would require an impairment analysis prior to our scheduled review.
	Stock-Based Compensation.
	All stock-based awards to date have exercise prices equal to the market price of our common stock on the date of grant and have ten-year contractual terms. Unvested options as of June 30, 2014 had vesting periods of one or three years from the date of grant. None of the stock options outstanding at June 30, 2014 are subject to performance or market-based vesting conditions.
	We measure and recognize compensation expense for all stock-based awards made to employees and directors. Compensation expense is based on the calculated fair value of the awards as measured at the grant date and is expensed over the service period of the awards.
	During the six months ended June 30, 2014 and 2013, we recorded compensation expense of $0.6 million and $0.2 million, respectively, within selling, general and administrative expense. As of June 30, 2014, the unrecognized compensation expense related to unvested stock awards, net of estimated forfeitures, was $1.4 million, which is expected to be recognized over a weighted-average period of 1.5 years.
	We granted 15,499 stock options during the quarter ended June 30, 2014. The fair value of the options granted was estimated on the grant date using the Black-Scholes option pricing model with the following assumptions: risk-free interest rates of 1.74% based on the U.S. Treasury yield in effect at the time of grant; dividend yields of zero percent; expected lives of 4.38 years, based on expected exercise activity behavior; and volatility of 83% based on the historical volatility of our common stock over a time that is consistent with the expected life of the option.
	Included in the stock awards outstanding as of June 30, 2014 were stock appreciation rights with respect to 83,333 and 55,000 shares of common stock granted to our Chief Executive Officer and Chief Financial Officer, respectively. These rights will vest over three years from the date of grant and have an exercise price of $4.32 per share, which is equal to the fair value of one share of our common stock on the date of grant, which was September 30, 2013.
	Net Sales Recognition.
	Revenue is realized and earned when all of the following criteria are met:
	•	Persuasive evidence of an arrangement exists;
	•	Delivery has occurred or services have been rendered;
	•	The seller’s price to the buyer is fixed or determinable; and
	•	Collectability is reasonably assured.
	For our Laboratory Services segment, net sales from Patient Testing labs are recognized on an individual test basis and take place when the test report is completed, reviewed and sent to the client less the reserve for insurance, Medicare and Medicaid contractual adjustments. There are no deferred net sales associated with our Patient Testing services. Adjustments to the allowances, based on actual receipts from third party payors, are reflected in the estimated contractual allowance applied prospectively. In our Biomarker Identification labs, we perform services on a project by project basis. When we receive payment in advance, we recognize revenue when we deliver the service. These projects typically do not extend beyond one year. At June 30, 2014 and December 31, 2013, deferred net sales associated with pharmacogenomics research projects, included in the balance sheet in deferred revenue was $0.3 million and $0.2 million, respectively.
	Net sales of products in our Genetic Assays and Platforms segment are recognized in accordance with the terms of the sales arrangement. Such recognition is based on receipt of an unconditional customer order and transfer of title and risk of ownership to the customer, typically upon shipment of the product under a purchase order. Our sales terms do not provide for the right of return unless the product is damaged or defective. Net sales from certain services associated with the analytical instruments, to be performed subsequent to shipment of the products, is deferred and recognized when the services are provided. Such services, mainly limited to installation and training services that are not essential to the functionality of the instruments, typically are performed in a timely manner subsequent to shipment of the instrument. We also enter into various service contracts that cover installed instruments. These contracts cover specific time periods, and net sales associated with these contracts are deferred and recognized ratably over the service period. At each of June 30, 2014 and December 31, 2013, deferred net revenue associated with our service contracts was $0.9 million and was included in the balance sheet in deferred revenue.
Common Stock Warrants.
Certain of our issued and outstanding warrants to purchase common stock do not qualify to be treated as equity and, accordingly, are recorded as a liability (“Common Stock Warrant Liability”). The Common Stock Warrant Liability was initially recorded at fair value using a Monte Carlo simulation model. We are required to present these instruments at fair value at each reporting date and any changes in fair values are recorded as an adjustment to earnings. The Common Stock Warrant Liability is considered a Level Three financial instrument for purposes of fair value measurement. See Note 9 - “Fair Value” to the notes to our accompanying unaudited condensed consolidated financial statements for additional information.
Translation of Foreign Currency.
Our foreign subsidiary uses the British Pound Sterling, which is the local currency of the country in which it is located, as its functional currency. Its assets and liabilities are translated into U.S. Dollars at the exchange rates in effect at the balance sheet date. A cumulative translation gain of $0.03 million was reported as other comprehensive income on the accompanying unaudited condensed consolidated statement of comprehensive loss for the six months ended June 30, 2014. A cumulative translation loss of $0.2 million was reported as accumulated other comprehensive income for the six months ended June 30, 2013. Revenues and expenses are translated at the average rates during the period. For transactions that are not denominated in the functional currency, we recognized less than $0.1 million as foreign currency transaction expense in the determination of net loss for the six months ended June 30, 2014 and less than $0.1 million as foreign currency transaction income in the determination of net loss for the six months ended June 30, 2013.
Loss Per Share.
Basic loss per share is calculated based on the weighted-average number of common shares outstanding during each period. Diluted loss per share includes shares issuable upon exercise of outstanding stock options, warrants or conversion rights that have exercise or conversion prices below the market value of our common stock. Options, warrants and conversion rights pertaining to 5,510,255 and 3,334,055 shares of our common stock have been excluded from the computation of diluted loss per share at June 30, 2014 and 2013, respectively. The options, warrants and conversion rights that were exercisable during the three and six months ended June 30, 2014 and 2013 were not included because the effect would be anti-dilutive due to the net loss.
Recent Accounting Pronouncements.
In April 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-08, Presentation of Financial Statements (Topic 205) and Property, Plant, and Equipment (Topic 360): Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity, which changes the criteria for reporting a discontinued operation. Under this standard, a disposal of part of an organization that has a major effect on its operations and financial results is a discontinued operation. This guidance is effective prospectively for us beginning January 1, 2015 with earlier application permitted, but only for disposals (or classifications as held for sale) that have not been reported previously. When adopted, we do not expect that this guidance will have a material impact on our financial condition, results of operations or cash flows.
In May 2014, the FASB issued ASU 2014-09 “Revenue from Contracts with Customers”. The guidance requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to a customer. The ASU will replace most existing revenue recognition guidance in generally accepted accounting principles in the U.S. when it becomes effective on January 1, 2017. Early application is not permitted, but the standard permits the use of either the retrospective or cumulative effect transition method. We have not selected a transition method and are currently evaluating the impact this guidance will have on our financial condition, results of operations and cash flows.

INVENTORIES

INVENTORIES	6 Months Ended
	Jun. 30, 2014
Inventory Disclosure [Abstract]	'
Inventories	'
	INVENTORIES
	Inventories (net of allowance for obsolescence) consisted of the following:
		Dollars in Thousands
		June 30,			December 31,
		2014			2013
	Finished goods	$	2,967		$	2,978
	Raw materials and work in process	1,663			1,567
	Demonstration inventory	222			211
		$	4,852		$	4,756
	Less allowance for obsolescence	(843		)	(799		)
	Total	$	4,009		$	3,957

INTANGIBLES_AND_OTHER_ASSETS

INTANGIBLES AND OTHER ASSETS	6 Months Ended
	Jun. 30, 2014
Goodwill and Intangible Assets Disclosure [Abstract]	'
Intangibles And Other Assets	'
	INTANGIBLES AND OTHER ASSETS
	Long-lived intangible assets and other assets consisted of the following:
		Dollars in Thousands
		June 30, 2014						31-Dec-13
		Cost		Accumulated		Net Book		Cost		Accumulated		Net Book
				Amortization		Value				Amortization		Value
	Intangibles—technology	$	9,009	$	3,586	$	5,423	$	9,009	$	3,175	$	5,834
	Intangibles—assay royalties	1,434		717		717		1,434		614		820
	Intangibles—third party payor relationships	367		86		281		367		73		294
	Intangibles—tradenames and trademarks	824		292		532		824		233		591
	Intangibles—customer relationships	652		76		576		652		54		598
	Intangibles—covenants not to compete	184		107		77		184		77		107
	Patents	1,216		372		844		1,153		336		817
	Intellectual property	266		51		215		170		36		134
		$	13,952	$	5,287	$	8,665	$	13,793	$	4,598	$	9,195
		Estimated Useful Life
	Technology	7-10 years
	Assay royalties	7 years
	Third party payor relationships	15 years
	Tradenames and trademarks	7 years
	Customer relationships	15 years
	Covenants not to compete	3 years
	Patents	Life of the patent
	Intellectual property	7 years
	Other assets include U.S. security deposits and deferred tax assets, net of applicable valuation allowances.
	Amortization expense for intangible assets was $0.3 million and $0.5 million during the three months ended June 30, 2014 and 2013, respectively. Amortization expense for intangible assets was $0.7 million and $0.9 million during the six months ended June 30, 2014 and 2013, respectively. Amortization expense for intangible assets is expected to be $1.4 million, $1.4 million, $1.3 million, $1.3 million and $1.0 million for the years ending December 31, 2014, 2015, 2016, 2017 and 2018, respectively.
	Based on the length of time our technology is expected to be used and an evaluation of the lives of similar technology in the industry, effective January 1, 2014, we increased the estimated useful lives of certain technologies acquired in 2010 and 2012 from 7 years to 10 years, which decreased loss from operations by $0.1 million and net loss by $0.1 million, or $0.01 per basic and diluted share, for the three months ended June 30, 2014.

DEBT

DEBT	6 Months Ended
	Jun. 30, 2014
Debt Disclosure [Abstract]	'
Debt	'
	DEBT
			Dollars in Thousands
			June 30, 2014			December 31, 2013
	Revolving Line of Credit(1)		$	3,000		$	2,560
	Term Loan(2)		3,902			4,000
	Total debt, including short-term debt		6,902			6,560
	Current maturities of long-term debt		(691		)	(242		)
	Long-term debt, net of current maturities		$	6,211		$	6,318
	On March 13, 2013 (the “Effective Date”), we entered into a Loan and Security Agreement with affiliates of Third Security, LLC (the “Lenders”) for (a) a revolving line of credit (the “Revolving Line”) with borrowing availability of up to $4.0 million, subject to reduction based on our eligible accounts receivable, and (b) a term loan (the “Term Loan”) of $4.0 million (the “Loan Agreement”). Proceeds were used to pay off a three year senior secured promissory note payable to PGxHealth, LLC, which was entered into on December 29, 2010 in conjunction with our acquisition of the FAMILION family of genetic tests, and for general corporate and working capital purposes.
	On August 2, 2013, we entered into an amendment to the Loan Agreement (the “Amendment”). The Amendment, which became effective as of June 30, 2013, reduced our future minimum revenue covenants under the Loan Agreement and modifies the interest rates applicable to the amounts advanced under the Revolving Line.
	On November 14, 2013, we entered into a second amendment to the Loan Agreement (the “Second Amendment”). The Second Amendment, which became effective as of October 31, 2013, reduced our future minimum revenue covenants under the Loan Agreement.
	On January 27, 2014, we entered into a third amendment to the Loan Agreement (the “Third Amendment”). Pursuant to the Third Amendment, the Lenders agreed to waive certain events of default under the Loan Agreement, and the parties amended certain provisions of the Loan Agreement, including the minimum liquidity ratio that we must maintain during the term of the Loan Agreement.
	On March 3, 2014, we entered into a fourth amendment to the Loan Agreement (the “Fourth Amendment”). The Fourth Amendment provides that we will not be required to make any principal or interest payments under the Term Loan for the period from March 1, 2014 through March 31, 2015. Accordingly, pursuant to the Loan Agreement as amended by the Fourth Amendment, the next principal and interest payment under the Term Loan will be due on April 1, 2015. The interest on the debt that is being deferred, and not paid, is being capitalized as part of the Term Loan. As of June 30, 2014, the amount of interest that has been capitalized is $0.1 million.
	-1	Revolving Line of Credit. Amounts advanced under the Revolving Line bear interest at an annual rate equal to the greater of (a) 4.25% or (b) the Wall Street Journal prime rate plus 1%. Interest is payable on a monthly basis, with the balance payable at the maturity of the Revolving Line. Under the Amendment, amounts advanced under the Revolving Line bear interest at an annual rate equal to the greater of (x) 6.25% or (y) the Wall Street Journal prime rate plus 3%. The current interest rate is 6.25%. Under the Loan Agreement, we paid the Lenders an upfront fee of $20,000, and will pay the Lenders an additional commitment fee of $20,000 on each one year anniversary of the Effective Date during the term of the Revolving Line. In addition, a fee of 0.5% per annum is payable quarterly on the unused portion of the Revolving Line. The Revolving Line matures on September 1, 2016.
	-2	Term Loan. We received $4.0 million under the Term Loan on the Effective Date. Pursuant to the terms of the Loan Agreement, as amended by the Fourth Amendment, we are required to make monthly payments of principal and interest to the Lenders commencing on April 1, 2015. The current interest rate is 9.1%.
	We paid the Lenders an upfront fee of $40,000 for the Term Loan, and will pay the Lenders an additional final payment of $120,000 at maturity or prepayment of the Term Loan. In addition, if we repay the Term Loan prior to maturity, we will pay the Lenders a prepayment penalty of 5% of the total outstanding balance under the Term Loan if the prepayment occurs within one year after the Effective Date, 2.5% of the total outstanding balance under the Term Loan if the prepayment occurs between one and two years after the Effective Date, and 1% of the total outstanding balance under the Term Loan if the prepayment occurs thereafter.
	Additional Terms
	The Loan Agreement contains affirmative and negative covenants. Under the Term Loan, we are required to maintain a minimum liquidity ratio and achieve a minimum amount of revenue, and we also agreed not to (i) pledge or otherwise encumber our assets other than to the Lenders, (ii) enter into additional borrowings or guarantees, (iii) repurchase our capital stock, or (iv) enter into certain mergers or acquisitions without the Lenders’ consent. Additionally, the Loan Agreement contains a subjective acceleration clause at the discretion of the Lenders. As of June 30, 2014, we were in compliance with all financial covenants.
	To secure the repayment of any amounts borrowed under the Revolving Line and the Term Loan, we granted the Lenders a security interest in all of our assets. The occurrence of an event of default under the Loan Agreement could result in the acceleration of our obligations under the Loan Agreement and would increase the applicable interest rate under the Revolving Line or Term Loan (or both) by 5%, and permit the Lenders to exercise remedies with respect to the collateral under the Loan Agreement.

COMMITMENTS_AND_CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	6 Months Ended
	Jun. 30, 2014
Commitments and Contingencies Disclosure [Abstract]	'
Commitments and Contingencies	'
	COMMITMENTS AND CONTINGENCIES
	From time to time we are subject to claims of various amounts, which arise out of the normal course of business. In the opinion of management, the disposition of pending claims will not have a material adverse effect on our financial position, results of operations or cash flows.
	We lease certain equipment, vehicles and operating facilities under non-cancellable operating leases that expire on various dates through 2022. The future minimum lease payments required under these leases are approximately $0.6 million for the remainder of 2014, $1.0 million in 2015, $0.9 million in 2016, $0.8 million in 2017, $0.5 million in 2018 and $0.9 million thereafter. Rent expense for the six months ended June 30, 2014 and 2013 was $0.5 million and $0.6 million, respectively. At June 30, 2014, firm commitments to vendors totaled $1.3 million.

INCOME_TAXES

INCOME TAXES	6 Months Ended
	Jun. 30, 2014
Income Tax Disclosure [Abstract]	'
Income Taxes	'
	INCOME TAXES
	We file income tax returns in the U.S. federal jurisdiction, various U.S. state jurisdictions and various foreign jurisdictions. We have statutes of limitation open for federal income tax returns related to tax years 2010 through 2013. We have state income tax returns subject to examination primarily for tax years 2010 through 2013. Open tax years related to foreign jurisdictions, primarily the United Kingdom, remain subject to examination for tax years 2010 through 2013.
	Income tax expense for the six months ended June 30, 2014 was $0.5 million. Income tax expense for the six months ended June 30, 2013 was $0.1 million. Our effective tax rate for the six months ended June 30, 2014 was 6.57%, which is primarily the result of valuation allowances against the net operating losses for the U.S., which results in us not recording net deferred tax assets in the U.S.
	Our goodwill is an indefinite-lived asset which is not amortized for financial reporting purposes. However, goodwill is tax deductible and therefore amortized for tax purposes. As such, deferred income tax expense and a deferred tax liability arise as a result of the tax-deductibility of the goodwill. The resulting deferred tax liability, which is expected to increase over time, will have an indefinite life, resulting in what is referred to as a “naked tax credit.” This deferred tax liability could remain on our balance sheet indefinitely unless there is an impairment of the goodwill (for financial reporting purposes), or there is a disposal of the business to which the goodwill relates. During the six months ended June 30, 2014, the amount of income tax expense related to the tax amortization of goodwill was $0.5 million. Of this amount, $0.4 million related to prior periods.
	During each of the three and six months ended June 30, 2014 and 2013, there were no material changes to the liability for uncertain tax positions.

STOCKHOLDERS_EQUITY

STOCKHOLDERS' EQUITY	6 Months Ended
	Jun. 30, 2014
Stockholders' Equity Note [Abstract]	'
Stockholders' Equity	'
	STOCKHOLDERS’ EQUITY
	Common Stock.
	Pursuant to our Third Amended and Restated Certificate of Incorporation as amended, we currently have 150,000,000 shares of common stock authorized for issuance.
	On February 2, 2012, we entered into definitive agreements with institutional and other accredited investors and raised approximately $22.0 million in a private placement financing (the “Private Placement”), which included an aggregate of $3.0 million in convertible notes issued in December 2011 to entities affiliated with Third Security, LLC, a related party, that automatically converted into shares of our common stock and warrants to purchase such common stock on the same terms as all investors in the Private Placement. Pursuant to the purchase agreement, we issued an aggregate of 1,583,333 shares of our common stock at a price per share of $12.00, as well as five-year warrants to purchase up to an aggregate of 823,333 shares of our common stock with an exercise price of $15.00 per share. In connection with the conversion of the convertible notes issued by us to the entities associated with Third Security, LLC, the entities received an aggregate of 250,000 shares of our common stock and 125,000 warrants on the same terms as all investors in the Private Placement. Craig-Hallum Capital Group LLC served as the sole placement agent for the offering. In consideration for services rendered as the placement agent in the offering, we agreed to (i) pay to the placement agent cash commissions equal to $1,330,000, or 7.0% of the gross proceeds received in the offering; (ii) issue to the placement agent a five-year warrant to purchase up to 31,666 shares of our common stock (representing 2% of the shares sold in the Private Placement) with an exercise price of $15.00 per share and other terms that are the same as the terms of the warrants issued in the Private Placement; and (iii) reimburse the placement agent for reasonable out-of-pocket expenses, including fees paid to the placement agent’s legal counsel, incurred in connection with the offering, which reimbursable expenses shall not exceed $125,000. The costs incurred to complete the Private Placement were recorded as a reduction in equity in the amount of $1.5 million. Net proceeds from this offering were used for general corporate and working capital purposes, primarily to accelerate development of several of our key initiatives.
	On January 24, 2013, we entered into a Securities Purchase Agreement with certain institutional and other accredited investors pursuant to which we: (i) sold to the investors an aggregate of 1,383,333 shares of our common stock at a price per share of $6.00 for aggregate gross proceeds of approximately $8.3 million; and (ii) issued to the investors warrants to purchase up to an aggregate of 691,656 shares of our common stock with an exercise price of $9.00 per share (the “Offering”). The warrants may be exercised, in whole or in part, at any time from January 30, 2013 until January 30, 2018 and contain both cash and “cashless exercise” features. Affiliates of Third Security, LLC, a related party, purchased an aggregate of 500,000 shares of common stock and warrants to purchase an aggregate of 250,000 shares of common stock in the Offering on the same terms as the other investors. We are using the net proceeds from the Offering for general corporate and working capital purposes, primarily to accelerate development of several of our key initiatives.
	In connection with the Offering, we entered into a registration rights agreement with the investors (the “Registration Rights Agreement”). The Registration Rights Agreement required that we file with the Securities and Exchange Commission a registration statement to register for resale the shares of common stock sold and the shares of common stock issuable upon exercise of the warrants (the “Warrant Shares”) by March 16, 2013. The registration statement was filed with the Securities and Exchange Commission on March 15, 2013 and was declared effective by the Securities and Exchange Commission on March 29, 2013.
	The Offering required the repricing and issuance of additional common stock warrants to the holders of warrants issued in the February 2012 common stock and warrant sale. The exercise price of the warrants decreased from $15.00 per share to $12.96 per share and the number of shares issuable upon exercise of the warrants increased from 948,333 to 1,097,600.
	Common Stock Warrants.
	During the six months ended June 30, 2014 and 2013, we issued warrants to purchase 115,065 and 691,656 shares of common stock, respectively. None of the issued warrants were exercised during such periods. The warrants issued in 2014 were issued due to repricing requirements contained in the warrants issued in the private placement in 2013. The warrants issued in 2013 were issued in connection with the sales of common stock on January 24, 2013. Warrants to purchase an aggregate of 2,335,348 shares of common stock were outstanding at June 30, 2014.
	Warrant Holder		Issue Year	Expiration	Underlying	Exercise
					Shares	Price
	Affiliates of Third Security, LLC(1)		2010	Dec-15	431,027	$6.96
	Various Institutional Holders(2)		2012	Feb-17	1,052,820	$11.73
	Affiliates of Third Security, LLC(2)		2012	Feb-17	159,845	$11.73
	Various Institutional Holders(3)		2013	Jan-18	441,656	$9.00
	Affiliates of Third Security, LLC(3)		2013	Jan-18	250,000	$9.00
					2,335,348
	-1	This warrant was issued in connection with the issuance of warrants to purchase shares of our Series A Preferred Stock to affiliates of Third Security, LLC in December 2010. The number of underlying shares shown reflects the number of shares of common stock issuable upon conversion of the shares of Series A Preferred Stock for which this warrant is currently exercisable.
	-2	These warrants were issued in connection with the Private Placement completed in February 2012 and are classified as a liability in our financial statements. See Footnote 9 - Fair Value. These warrants also contain certain anti-dilution provisions that provide for an adjustment to the exercise price and number of shares issuable upon exercise of the warrant in the event that we engage in certain issuances of shares of our common stock at a price lower than the exercise price of the warrant.
	-3	These warrants were issued in connection with the Offering, which was completed in January 2013.
	Issuance of Series B Preferred Stock
	On March 5, 2014, we entered into a Series B Convertible Preferred Stock Purchase Agreement (the “Series B Purchase Agreement”) with affiliates of Third Security, LLC (the “2014 Third Security Investors”), pursuant to which we, in a private placement, sold and issued an aggregate of 1,443,297 shares of our Series B Preferred Stock, par value $0.01 per share (the “Series B Preferred Stock”) at a price per share of $4.85 for an aggregate purchase price of approximately $7.0 million. Each share of Series B Preferred Stock issued pursuant to the Series B Purchase Agreement is initially convertible into shares of our common stock at a rate of 1-for-1, which conversion rate is subject to further adjustment as set forth in the Certificate of Designation of Series B Convertible Preferred Stock.
	In connection with the Series B financing, we also entered into a Registration Rights Agreement, dated March 5, 2014, with the 2014 Third Security Investors, pursuant to which we granted certain demand, “piggy-back” and S-3 registrations rights covering the resale of the shares of common stock underlying the Series B Preferred Stock issued pursuant to the Series B Purchase Agreement and all shares of common stock issuable upon any dividend or other distribution with respect thereto.
	The Series B financing required the repricing and issuance of additional common stock warrants to the holders of warrants issued in the February 2012 common stock and warrant sale. The exercise price of the warrants decreased from $12.96 per share to $11.73 per share and the number of shares issuable upon exercise of the warrants increased from 1,097,600 to 1,212,665.

FAIR_VALUE

FAIR VALUE	6 Months Ended
	Jun. 30, 2014
Fair Value Disclosures [Abstract]	'
Fair Value	'
	FAIR VALUE
	FASB guidance on fair value measurements, which defines fair value, establishes a framework for measuring fair value and expands disclosures about fair value measurements for our financial assets and liabilities, as well as for other assets and liabilities that are carried at fair value on a recurring basis in our consolidated financial statements.
	FASB guidance establishes a three-level fair value hierarchy based upon the assumptions (inputs) used to price assets or liabilities. The three levels of inputs used to measure fair value are as follows:
	Level 1—Unadjusted quoted prices in active markets for identical assets or liabilities;
	Level 2—Observable inputs other than those included in Level 1, such as quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets or liabilities in inactive markets; and
	Level 3—Unobservable inputs reflecting our own assumptions and best estimate of what inputs market participants would use in pricing the asset or liability.
	Debt.
	Our long term debt is considered a Level 3 liability for which book value approximates fair market value due to the variable interest rate it bears.
	Common Stock Warrant Liability.
	Certain of our issued and outstanding warrants to purchase shares of common stock do not qualify to be treated as equity, and accordingly are recorded as a liability. The Common Stock Warrant Liability represents the fair value of the 1.2 million warrants issued in February 2012. We are required to record these instruments at fair value at each reporting date and changes are recorded as a non-cash adjustment to earnings. The gains or losses included in earnings are reported in other income (expense) in our Statement of Operations. Management does not believe that this liability will be settled by a use of cash.
	The Common Stock Warrant Liability is considered a Level 3 financial instrument and is valued using a Monte Carlo simulation. This method is well suited to valuing options with non-standard features, such as anti-dilution protection. A Monte Carlo simulation model uses repeated random sampling to simulate significant uncertainty in inputs. Assumptions and inputs used in the valuation of the common stock warrants are broken down into four sections: Static Business Inputs; Static Technical Inputs; Simulated Business Inputs; and Simulated Technical Inputs.
	Static Business Inputs include: our equity value, which was estimated using our stock price of $3.74 as of June 30, 2014; the amount of the down-round financing; the timing of the down-round financing; the expected exercise period of 2.61 years from the valuation date; and the fact that no other potential fundamental transactions are expected during the term of the common stock warrants.
	Static Technical Inputs include: volatility of 55% and the risk-free interest rate of 0.68% based on the 2.5-year U.S. Treasury yield interpolated from the two-year and three-year U.S. Treasury bonds.
	Simulated Business Inputs include: the probability of down-round financing, which was estimated to be 25% for simulated equity values below the down-round financing cut-off point.
	Simulated Technical Inputs include: our equity value, which in periods 1-10 follows a geometric Brownian motion and is simulated over 10 independent six-month periods; and a down-round financing event that was randomly simulated in an iteration based on the 25% discrete probability of a down-round financing for those iterations where our simulated equity value at the expected timing of down-round financing was below the down-round financing cut-off point.
	During the three months ended June 30, 2014 and 2013, the changes in the fair value of the liability measured using significant unobservable inputs (Level 3) was comprised of the following:
		Dollars in Thousands
		For the Three Months Ended
		June 30, 2014			June 30, 2013
	Beginning balance at April 1	$	550		$	500
	Total gains or losses:
	Recognized in earnings	(200		)	(200		)
	Balance at June 30	$	350		$	300
	During the six months ended June 30, 2014 and 2013, the changes in the fair value of the liability measured using significant unobservable inputs (Level 3) was comprised of the following:
		Dollars in Thousands
		For the Six Months Ended
		June 30, 2014			June 30, 2013
	Beginning balance at January 1	$	600		$	900
	Total gains or losses:
	Recognized in earnings	(250		)	(600		)
	Balance at June 30	$	350		$	300
	The change in unrealized gains or losses of Level 3 liabilities was included in earnings and was reported in other income (expense) in our Statement of Operations.

STOCK_OPTIONS

STOCK OPTIONS	6 Months Ended
	Jun. 30, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Stock Options	'
	STOCK OPTIONS
	Stock Options.
	The following table summarizes stock option activity during the six months ended June 30, 2014:
		Number of		Weighted-Average
		Options		Exercise Price
	Balance at January 1, 2014	565,028		$	7.19
	Granted	214,296		5.47
	Forfeited	(47,559	)	5.07
	Expired	(545	)	14.28
	Balance at June 30, 2014	731,220		$	6.82
	Exercisable at June 30, 2014	194,663		$	11.03
	During the six months ended June 30, 2014, we granted options to purchase 214,296 shares of our common stock at a weighted-average exercise price of $5.47 per share under our 2006 Equity Incentive Plan (the “Plan”). Options to purchase an aggregate of 159,375 shares of our common stock were granted during the six months ended June 30, 2013.
	As of June 30, 2014, there were 731,220 options exercisable or expected to vest with an aggregate intrinsic value of zero.
	Stock Appreciation Rights (“SARs”)
	The following table summarizes SARs activity under the Plan during the six months ended June 30, 2014:
		Number of		Weighted-Average
		Options		Exercise Price
	Balance at January 1, 2014	138,333		$	4.32
	Balance at June 30, 2014	138,333		$	4.32
	Exercisable at June 30, 2014	—		$	—
	All SARs outstanding were issued solely to our executive officers.
	As of June 30, 2014, 138,333 shares subject to outstanding SARs were expected to vest. The weighted-average exercise price of these SARs was $4.32 and the aggregate intrinsic value was zero.

OPERATING_SEGMENT_AND_GEOGRAPH

OPERATING SEGMENT AND GEOGRAPHIC INFORMATION	6 Months Ended
	Jun. 30, 2014
Segment Reporting [Abstract]	'
Operating Segment And Geographic Information	'
	OPERATING SEGMENT AND GEOGRAPHIC INFORMATION
	Our chief operating decision-maker is our Chief Executive Officer, who regularly evaluates our performance based on net sales and net loss before taxes. The preparation of this segment analysis requires management to make estimates and assumptions around expenses below the gross profit level. While we believe the segment information to be directionally correct, actual results could differ from the estimates and assumptions used in preparing this information.
	We have two complementary reportable operating segments, Laboratory Services and Genetic Assays and Platforms.
	Segment information for the three months ended June 30, 2014 and 2013 is as follows:
		Dollars in Thousands
		Three Months Ended June 30, 2014
		Laboratory Services			Genetic Assays			Total
					and Platforms
	Net Sales	$	3,843		$	2,921		$	6,764
	Gross Profit	1,490			903			2,393
	Net Loss before Taxes	(3,277		)	(624		)	(3,901		)
	Income Tax Expense (Benefit)	40			(48		)	(8		)
	Net Loss	$	(3,317	)	$	(576	)	$	(3,893	)
	Depreciation/Amortization	$	438		$	50		$	488
	Interest Expense, net	$	83		$	63		$	146
		30-Jun-14
	Total Assets	$	23,370		$	7,721		$	31,091
		Dollars in Thousands
		Three Months Ended June 30, 2013
		Laboratory Services			Genetic Assays			Total
					and Platforms
	Net Sales	$	4,012		$	3,294		$	7,306
	Gross Profit	1,853			1,120			2,973
	Net Loss before Taxes	(2,181		)	(692		)	(2,873		)
	Income Tax Expense	—			(6		)	(6		)
	Net Loss	$	(2,181	)	$	(686	)	$	(2,867	)
	Depreciation/Amortization	$	646		$	41		$	687
	Interest Expense, net	$	84		$	67		$	151
		30-Jun-13
	Total Assets	$	27,834		$	11,529		$	39,363
	Segment information for the six months ended June 30, 2014 and 2013 is as follows:
		Dollars in Thousands
		Six Months Ended June 30, 2014
		Laboratory Services			Genetic Assays			Total
					and Platforms
	Net Sales	$	7,531		$	5,484		$	13,015
	Gross Profit	3,122			1,765			4,887
	Net Loss before Taxes	(6,261		)	(1,311		)	(7,572		)
	Income Tax Expense (Benefit)	549			(52		)	497
	Net Loss	$	(6,810	)	$	(1,259	)	$	(8,069	)
	Depreciation/Amortization	$	878		$	103		$	981
	Interest Expense, net	$	190		$	138		$	328
		Dollars in Thousands
		Six Months Ended June 30, 2013
		Laboratory Services			Genetic Assays			Total
					and Platforms
	Net Sales	$	8,439		$	6,241		$	14,680
	Gross Profit	4,046			2,182			6,228
	Net Loss before Taxes	(5,267		)	(1,127		)	(6,394		)
	Income Tax Expense (Benefit)	—			60			60
	Net Loss	$	(5,267	)	$	(1,187	)	$	(6,454	)
	Depreciation/Amortization	$	1,209		$	222		$	1,431
	Interest Expense, net	$	219		$	85		$	304
	Net sales for the three and six months ended June 30, 2014 and 2013 by country were as follows:
		Dollars in Thousands						Dollars in Thousands
		Three Months Ended June 30,						Six Months Ended June 30,
		2014			2013			2014			2013
	United States	$	4,870		$	5,797		$	9,633		$	11,146
	Italy	337			372			722			827
	All Other Countries	1,557			1,137			2,660			2,707
	Total	$	6,764		$	7,306		$	13,015		$	14,680
	Other than the countries specifically identified above, no other country individually accounted for more than 5% of total net sales.
	Approximately 99% of our long-lived assets are located within the United States.

SUBSEQUENT_EVENTS

SUBSEQUENT EVENTS	6 Months Ended
	Jun. 30, 2014
Subsequent Events [Abstract]	'
Subsequent Events	'
	SUBSEQUENT EVENTS
	Events or transactions that occur after the balance sheet date, but before the financial statements are complete, are reviewed to determine if they should be recognized.
	On July 1, 2014, the Collaboration Agreement, dated October 9, 2013, between Transgenomic and PDI, Inc., a Delaware corporation d/b/a Interpace Diagnostics for the promotion of our CardioPredict test expired automatically pursuant to its terms upon the parties’ completion of phase one under the agreement. Our management believes that the test continues to have good commercial potential and is evaluating commercialization options.
	On July 1, 2014, we entered into a Surveyor Kit Patent, Technology, and Inventory Purchase Agreement (the “Purchase Agreement”) with Integrated DNA Technologies, Inc. (“IDT”). Pursuant to the Purchase Agreement, on July 1, 2014, we transferred and sold to IDT all of our right, title and interest in and to our Surveyor Kits product line and related technology, including, without limitation, all patents, patent applications, licenses, technology, know-how and trademarks relating to the Surveyor Kits product line technology, and our inventory of Surveyor products (collectively, the “Surveyor Technology”).
	In consideration for the purchase of the Surveyor Technology, IDT paid us an initial payment of $3.65 million. As additional consideration, IDT will pay us an additional amount equal to an aggregate of $600,000 in four equal installments, the first of which must be made by October 1, 2014, and the last of which must be made by July 1, 2015. Additionally, if net sales of the Surveyor Kits by IDT exceed a certain threshold during the period beginning on October 1, 2014 and ending on September 30, 2015, IDT will be obligated to pay us an additional earn-out payment equal to a percentage of the net sales exceeding the threshold that is in the middle double digits.
	Pursuant to the Purchase Agreement, IDT granted us a worldwide, irrevocable, exclusive, fully paid-up, royalty-free, transferable right and license to the Surveyor Technology for clinical uses, including, without limitation, the provision of diagnostic and pharmaceutical services, and any other clinical uses in connection with our biomarker identification business unit.

SUMMARY_OF_SIGNIFICANT_ACCOUNT1

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	6 Months Ended
	Jun. 30, 2014
Accounting Policies [Abstract]	'
Basis of Presentation	'
	Basis of Presentation.
	The condensed consolidated balance sheet as of December 31, 2013 was derived from our audited balance sheet as of that date. The accompanying condensed consolidated financial statements as of and for the three and six months ended June 30, 2014 and 2013 are unaudited and reflect all adjustments (consisting of only normal recurring adjustments) that are, in the opinion of management, necessary for a fair presentation of the financial position and operating results for the interim periods. These unaudited condensed consolidated financial statements and notes should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December 31, 2013 contained in our Annual Report on Form 10-K, filed with the Securities and Exchange Commission on March 27, 2014. The results of operations for the interim periods presented are not necessarily indicative of the results for the entire year.
	Following approval of our stockholders, on January 15, 2014, our Board of Directors approved a reverse split of our common stock, par value $0.01, at a ratio of one-for-twelve. This reverse stock split became effective on January 27, 2014 and, unless otherwise indicated, all share amounts, per share data, share prices, exercise prices and conversion rates set forth in these notes and the accompanying consolidated financial statements have, where applicable, been adjusted retroactively to reflect this reverse stock split.
Principles of Consolidation	'
	Principles of Consolidation.
	The consolidated financial statements include the accounts of Transgenomic, Inc. and our wholly owned subsidiary. All inter-company balances and transactions have been eliminated in consolidation.
Risks and Uncertainties	'
	Risks and Uncertainties.
	Certain risks and uncertainties are inherent in our day-to-day operations and in the process of preparing our financial statements. The more significant of those risks are presented below and throughout the notes to the unaudited condensed consolidated financial statements.
Use of Estimates	'
	Use of Estimates.
	The preparation of condensed consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of net sales and expenses during the reporting period. In addition, estimates and assumptions associated with the determination of the fair value of certain assets and related impairments require considerable judgment by management. Actual results could differ from the estimates and assumptions used in preparing these consolidated financial statements.
Reclassifications	'
	Reclassifications.
	Certain prior period amounts of selling, general and administrative expenses have been reclassified to cost of goods sold in order to conform to the current period presentation. These reclassifications had no effect on previously reported net earnings
Fair Value	'
	Fair Value.
	Unless otherwise specified, book value approximates fair market value. The common stock warrant liability is recorded at fair value.
Cash and Cash Equivalents	'
	Cash and Cash Equivalents.
	Cash and cash equivalents include cash and investments with original maturities at the date of acquisition of three months or less.
Concentration of Cash	'
	Concentrations of Cash.
	From time to time, we may maintain a cash position with financial institutions in amounts that exceed federally insured limits. We have not experienced any losses on such accounts as of June 30, 2014.
Accounts Receivable	'
	While payment terms are generally 30 days, we have also provided extended payment terms in certain cases. In addition, we operate globally and the payment terms for some of our international customers may be greater than 90 days. Accounts receivable are carried at original invoice amount and shown net of allowance for doubtful accounts and contractual allowances. The estimate made for doubtful accounts is based on a review of all outstanding amounts on a quarterly basis. We determine the allowance for doubtful accounts by assigning a consistent reserve percentage to each accounts receivable aging category and contractual allowances by regularly evaluating individual customer payment history. Accounts receivable are written off when deemed uncollectible and all collection efforts have been exhausted.
Inventories	'
	Inventories.
	Inventories are stated at the lower of cost or market net of allowance for obsolete inventory. Cost is computed using standard costs for finished goods and average or latest actual cost for raw materials and work in process, which approximates the first-in, first-out (FIFO) method.
Inventory Obsolescence	'
	We determine the allowance for obsolescence by evaluating inventory quarterly for items deemed to be slow moving or obsolete.
Property and Equipment	'
	Property and Equipment.
	Property and equipment are carried at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the related assets
Goodwill	'
	Goodwill.
	Goodwill is tested for impairment annually. We perform this impairment analysis during the fourth quarter of each year or when a significant event occurs that may impact goodwill. Impairment occurs when the carrying value is determined to be not recoverable, thereby causing the carrying value of the goodwill to exceed its fair value. If impaired, the asset’s carrying value is reduced to its fair value. No events have transpired in the six months ended June 30, 2014 that would require an impairment analysis prior to our scheduled review.
Stock Based Compensation	'
	Stock-Based Compensation.
	All stock-based awards to date have exercise prices equal to the market price of our common stock on the date of grant and have ten-year contractual terms. Unvested options as of June 30, 2014 had vesting periods of one or three years from the date of grant. None of the stock options outstanding at June 30, 2014 are subject to performance or market-based vesting conditions.
	We measure and recognize compensation expense for all stock-based awards made to employees and directors. Compensation expense is based on the calculated fair value of the awards as measured at the grant date and is expensed over the service period of the awards.
Net Sales Recognition	'
	Net Sales Recognition.
	Revenue is realized and earned when all of the following criteria are met:
	•	Persuasive evidence of an arrangement exists;
	•	Delivery has occurred or services have been rendered;
	•	The seller’s price to the buyer is fixed or determinable; and
	•	Collectability is reasonably assured.
	For our Laboratory Services segment, net sales from Patient Testing labs are recognized on an individual test basis and take place when the test report is completed, reviewed and sent to the client less the reserve for insurance, Medicare and Medicaid contractual adjustments. There are no deferred net sales associated with our Patient Testing services. Adjustments to the allowances, based on actual receipts from third party payors, are reflected in the estimated contractual allowance applied prospectively. In our Biomarker Identification labs, we perform services on a project by project basis. When we receive payment in advance, we recognize revenue when we deliver the service. These projects typically do not extend beyond one year. At June 30, 2014 and December 31, 2013, deferred net sales associated with pharmacogenomics research projects, included in the balance sheet in deferred revenue was $0.3 million and $0.2 million, respectively.
	Net sales of products in our Genetic Assays and Platforms segment are recognized in accordance with the terms of the sales arrangement. Such recognition is based on receipt of an unconditional customer order and transfer of title and risk of ownership to the customer, typically upon shipment of the product under a purchase order. Our sales terms do not provide for the right of return unless the product is damaged or defective. Net sales from certain services associated with the analytical instruments, to be performed subsequent to shipment of the products, is deferred and recognized when the services are provided. Such services, mainly limited to installation and training services that are not essential to the functionality of the instruments, typically are performed in a timely manner subsequent to shipment of the instrument. We also enter into various service contracts that cover installed instruments. These contracts cover specific time periods, and net sales associated with these contracts are deferred and recognized ratably over the service period. At each of June 30, 2014 and December 31, 2013, deferred net revenue associated with our service contracts was $0.9 million and was included in the balance sheet in deferred revenue.
Common Stock Warrants	'
	Common Stock Warrants.
	Certain of our issued and outstanding warrants to purchase common stock do not qualify to be treated as equity and, accordingly, are recorded as a liability (“Common Stock Warrant Liability”). The Common Stock Warrant Liability was initially recorded at fair value using a Monte Carlo simulation model. We are required to present these instruments at fair value at each reporting date and any changes in fair values are recorded as an adjustment to earnings. The Common Stock Warrant Liability is considered a Level Three financial instrument for purposes of fair value measurement.
Translation of Foreign Currency	'
	Translation of Foreign Currency.
	Our foreign subsidiary uses the British Pound Sterling, which is the local currency of the country in which it is located, as its functional currency. Its assets and liabilities are translated into U.S. Dollars at the exchange rates in effect at the balance sheet date.
Loss Per Share	'
	Loss Per Share.
	Basic loss per share is calculated based on the weighted-average number of common shares outstanding during each period. Diluted loss per share includes shares issuable upon exercise of outstanding stock options, warrants or conversion rights that have exercise or conversion prices below the market value of our common stock.
Recently Accounting Pronouncements	'
	Recent Accounting Pronouncements.
	In April 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-08, Presentation of Financial Statements (Topic 205) and Property, Plant, and Equipment (Topic 360): Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity, which changes the criteria for reporting a discontinued operation. Under this standard, a disposal of part of an organization that has a major effect on its operations and financial results is a discontinued operation. This guidance is effective prospectively for us beginning January 1, 2015 with earlier application permitted, but only for disposals (or classifications as held for sale) that have not been reported previously. When adopted, we do not expect that this guidance will have a material impact on our financial condition, results of operations or cash flows.
	In May 2014, the FASB issued ASU 2014-09 “Revenue from Contracts with Customers”. The guidance requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to a customer. The ASU will replace most existing revenue recognition guidance in generally accepted accounting principles in the U.S. when it becomes effective on January 1, 2017. Early application is not permitted, but the standard permits the use of either the retrospective or cumulative effect transition method. We have not selected a transition method and are currently evaluating the impact this guidance will have on our financial condition, results of operations and cash flows.

SUMMARY_OF_SIGNIFICANT_ACCOUNT2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	6 Months Ended
	Jun. 30, 2014
Accounting Policies [Abstract]	'
Allowance for doubtful accounts rollforward	'
	The following is a summary of activity for the allowance for doubtful accounts during the three and six months ended June 30, 2014 and 2013:
		Dollars in Thousands
		Beginning		Provision		Write-Offs			Ending
		Balance							Balance
	Three Months Ended June 30, 2014	$	3,540	$	850	$	(349	)	$	4,041
	Three Months Ended June 30, 2013	$	2,549	$	608	$	(795	)	$	2,362
	Six Months Ended June 30, 2014	$	3,838	$	1,523	$	(1,320	)	$	4,041
	Six Months Ended June 30, 2013	$	2,171	$	2,197	$	(2,006	)	$	2,362
Allowance for obsolete inventory rollforward	'
	The following is a summary of activity for the allowance for obsolete inventory during the three and six months ended June 30, 2014 and 2013:
		Dollars in Thousands
		Beginning		Provision		Write-Offs			Ending
		Balance							Balance
	Three Months Ended June 30, 2014	$	849	$	—	$	(6	)	$	843
	Three Months Ended June 30, 2013	$	611	$	—	$	(18	)	$	593
	Six Months Ended June 30, 2014	$	799	$	55	$	(11	)	$	843
	Six Months Ended June 30, 2013	$	616	$	—	$	(23	)	$	593
Schedule of property and equipment, useful lives	'
	Depreciation is computed using the straight-line method over the estimated useful lives of the related assets as follows:
	Leasehold improvements	1 to 10 years
	Furniture and fixtures	3 to 7 years
	Production equipment	3 to 7 years
	Computer equipment	3 to 7 years
	Research and development equipment	2 to 7 years

INVENTORIES_Tables

INVENTORIES (Tables)	6 Months Ended
	Jun. 30, 2014
Inventory Disclosure [Abstract]	'
Inventories	'
	Inventories (net of allowance for obsolescence) consisted of the following:
		Dollars in Thousands
		June 30,			December 31,
		2014			2013
	Finished goods	$	2,967		$	2,978
	Raw materials and work in process	1,663			1,567
	Demonstration inventory	222			211
		$	4,852		$	4,756
	Less allowance for obsolescence	(843		)	(799		)
	Total	$	4,009		$	3,957

INTANGIBLES_AND_OTHER_ASSETS_T

INTANGIBLES AND OTHER ASSETS (Tables)	6 Months Ended
	Jun. 30, 2014
Goodwill and Intangible Assets Disclosure [Abstract]	'
Schedule of Indefinite-Lived and Finite-Lived Intangible Assets	'
	Long-lived intangible assets and other assets consisted of the following:
		Dollars in Thousands
		June 30, 2014						31-Dec-13
		Cost		Accumulated		Net Book		Cost		Accumulated		Net Book
				Amortization		Value				Amortization		Value
	Intangibles—technology	$	9,009	$	3,586	$	5,423	$	9,009	$	3,175	$	5,834
	Intangibles—assay royalties	1,434		717		717		1,434		614		820
	Intangibles—third party payor relationships	367		86		281		367		73		294
	Intangibles—tradenames and trademarks	824		292		532		824		233		591
	Intangibles—customer relationships	652		76		576		652		54		598
	Intangibles—covenants not to compete	184		107		77		184		77		107
	Patents	1,216		372		844		1,153		336		817
	Intellectual property	266		51		215		170		36		134
		$	13,952	$	5,287	$	8,665	$	13,793	$	4,598	$	9,195
		Estimated Useful Life
	Technology	7-10 years
	Assay royalties	7 years
	Third party payor relationships	15 years
	Tradenames and trademarks	7 years
	Customer relationships	15 years
	Covenants not to compete	3 years
	Patents	Life of the patent
	Intellectual property	7 years

DEBT_Tables

DEBT (Tables)	6 Months Ended
	Jun. 30, 2014
Debt Disclosure [Abstract]	'
Schedule of Debt	'
			Dollars in Thousands
			June 30, 2014			December 31, 2013
	Revolving Line of Credit(1)		$	3,000		$	2,560
	Term Loan(2)		3,902			4,000
	Total debt, including short-term debt		6,902			6,560
	Current maturities of long-term debt		(691		)	(242		)
	Long-term debt, net of current maturities		$	6,211		$	6,318
	On March 13, 2013 (the “Effective Date”), we entered into a Loan and Security Agreement with affiliates of Third Security, LLC (the “Lenders”) for (a) a revolving line of credit (the “Revolving Line”) with borrowing availability of up to $4.0 million, subject to reduction based on our eligible accounts receivable, and (b) a term loan (the “Term Loan”) of $4.0 million (the “Loan Agreement”). Proceeds were used to pay off a three year senior secured promissory note payable to PGxHealth, LLC, which was entered into on December 29, 2010 in conjunction with our acquisition of the FAMILION family of genetic tests, and for general corporate and working capital purposes.
	On August 2, 2013, we entered into an amendment to the Loan Agreement (the “Amendment”). The Amendment, which became effective as of June 30, 2013, reduced our future minimum revenue covenants under the Loan Agreement and modifies the interest rates applicable to the amounts advanced under the Revolving Line.
	On November 14, 2013, we entered into a second amendment to the Loan Agreement (the “Second Amendment”). The Second Amendment, which became effective as of October 31, 2013, reduced our future minimum revenue covenants under the Loan Agreement.
	On January 27, 2014, we entered into a third amendment to the Loan Agreement (the “Third Amendment”). Pursuant to the Third Amendment, the Lenders agreed to waive certain events of default under the Loan Agreement, and the parties amended certain provisions of the Loan Agreement, including the minimum liquidity ratio that we must maintain during the term of the Loan Agreement.
	On March 3, 2014, we entered into a fourth amendment to the Loan Agreement (the “Fourth Amendment”). The Fourth Amendment provides that we will not be required to make any principal or interest payments under the Term Loan for the period from March 1, 2014 through March 31, 2015. Accordingly, pursuant to the Loan Agreement as amended by the Fourth Amendment, the next principal and interest payment under the Term Loan will be due on April 1, 2015. The interest on the debt that is being deferred, and not paid, is being capitalized as part of the Term Loan. As of June 30, 2014, the amount of interest that has been capitalized is $0.1 million.
	-1	Revolving Line of Credit. Amounts advanced under the Revolving Line bear interest at an annual rate equal to the greater of (a) 4.25% or (b) the Wall Street Journal prime rate plus 1%. Interest is payable on a monthly basis, with the balance payable at the maturity of the Revolving Line. Under the Amendment, amounts advanced under the Revolving Line bear interest at an annual rate equal to the greater of (x) 6.25% or (y) the Wall Street Journal prime rate plus 3%. The current interest rate is 6.25%. Under the Loan Agreement, we paid the Lenders an upfront fee of $20,000, and will pay the Lenders an additional commitment fee of $20,000 on each one year anniversary of the Effective Date during the term of the Revolving Line. In addition, a fee of 0.5% per annum is payable quarterly on the unused portion of the Revolving Line. The Revolving Line matures on September 1, 2016.
	-2	Term Loan. We received $4.0 million under the Term Loan on the Effective Date. Pursuant to the terms of the Loan Agreement, as amended by the Fourth Amendment, we are required to make monthly payments of principal and interest to the Lenders commencing on April 1, 2015. The current interest rate is 9.1%.
	We paid the Lenders an upfront fee of $40,000 for the Term Loan, and will pay the Lenders an additional final payment of $120,000 at maturity or prepayment of the Term Loan. In addition, if we repay the Term Loan prior to maturity, we will pay the Lenders a prepayment penalty of 5% of the total outstanding balance under the Term Loan if the prepayment occurs within one year after the Effective Date, 2.5% of the total outstanding balance under the Term Loan if the prepayment occurs between one and two years after the Effective Date, and 1% of the total outstanding balance under the Term Loan if the prepayment occurs thereafter.
	Additional Terms
	The Loan Agreement contains affirmative and negative covenants. Under the Term Loan, we are required to maintain a minimum liquidity ratio and achieve a minimum amount of revenue, and we also agreed not to (i) pledge or otherwise encumber our assets other than to the Lenders, (ii) enter into additional borrowings or guarantees, (iii) repurchase our capital stock, or (iv) enter into certain mergers or acquisitions without the Lenders’ consent. Additionally, the Loan Agreement contains a subjective acceleration clause at the discretion of the Lenders. As of June 30, 2014, we were in compliance with all financial covenants.
	To secure the repayment of any amounts borrowed under the Revolving Line and the Term Loan, we granted the Lenders a security interest in all of our assets. The occurrence of an event of default under the Loan Agreement could result in the acceleration of our obligations under the Loan Agreement and would increase the applicable interest rate under the Revolving Line or Term Loan (or both) by 5%, and permit the Lenders to exercise remedies with respect to the collateral under the Loan Agreement.

STOCKHOLDERS_EQUITY_Tables

STOCKHOLDERS' EQUITY (Tables)	6 Months Ended
	Jun. 30, 2014
Stockholders' Equity Note [Abstract]	'
Schedule of Stockholders' Equity Note, Warrants or Rights	'
	Warrants to purchase an aggregate of 2,335,348 shares of common stock were outstanding at June 30, 2014.
	Warrant Holder		Issue Year	Expiration	Underlying	Exercise
					Shares	Price
	Affiliates of Third Security, LLC(1)		2010	Dec-15	431,027	$6.96
	Various Institutional Holders(2)		2012	Feb-17	1,052,820	$11.73
	Affiliates of Third Security, LLC(2)		2012	Feb-17	159,845	$11.73
	Various Institutional Holders(3)		2013	Jan-18	441,656	$9.00
	Affiliates of Third Security, LLC(3)		2013	Jan-18	250,000	$9.00
					2,335,348
	-1	This warrant was issued in connection with the issuance of warrants to purchase shares of our Series A Preferred Stock to affiliates of Third Security, LLC in December 2010. The number of underlying shares shown reflects the number of shares of common stock issuable upon conversion of the shares of Series A Preferred Stock for which this warrant is currently exercisable.
	-2	These warrants were issued in connection with the Private Placement completed in February 2012 and are classified as a liability in our financial statements. See Footnote 9 - Fair Value. These warrants also contain certain anti-dilution provisions that provide for an adjustment to the exercise price and number of shares issuable upon exercise of the warrant in the event that we engage in certain issuances of shares of our common stock at a price lower than the exercise price of the warrant.
	-3	These warrants were issued in connection with the Offering, which was completed in January 2013.

FAIR_VALUE_Tables

FAIR VALUE (Tables)	6 Months Ended
	Jun. 30, 2014
Fair Value Disclosures [Abstract]	'
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation	'
	During the three months ended June 30, 2014 and 2013, the changes in the fair value of the liability measured using significant unobservable inputs (Level 3) was comprised of the following:
		Dollars in Thousands
		For the Three Months Ended
		June 30, 2014			June 30, 2013
	Beginning balance at April 1	$	550		$	500
	Total gains or losses:
	Recognized in earnings	(200		)	(200		)
	Balance at June 30	$	350		$	300
	During the six months ended June 30, 2014 and 2013, the changes in the fair value of the liability measured using significant unobservable inputs (Level 3) was comprised of the following:
		Dollars in Thousands
		For the Six Months Ended
		June 30, 2014			June 30, 2013
	Beginning balance at January 1	$	600		$	900
	Total gains or losses:
	Recognized in earnings	(250		)	(600		)
	Balance at June 30	$	350		$	300

STOCK_OPTIONS_Tables

STOCK OPTIONS (Tables)	6 Months Ended
	Jun. 30, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Disclosure of Share-based Compensation Arrangements by Share-based Payment Award	'
	The following table summarizes stock option activity during the six months ended June 30, 2014:
		Number of		Weighted-Average
		Options		Exercise Price
	Balance at January 1, 2014	565,028		$	7.19
	Granted	214,296		5.47
	Forfeited	(47,559	)	5.07
	Expired	(545	)	14.28
	Balance at June 30, 2014	731,220		$	6.82
	Exercisable at June 30, 2014	194,663		$	11.03
Schedule of Other Share-based Compensation, Activity	'
	The following table summarizes SARs activity under the Plan during the six months ended June 30, 2014:
		Number of		Weighted-Average
		Options		Exercise Price
	Balance at January 1, 2014	138,333		$	4.32
	Balance at June 30, 2014	138,333		$	4.32
	Exercisable at June 30, 2014	—		$	—

OPERATING_SEGMENT_AND_GEOGRAPH1

OPERATING SEGMENT AND GEOGRAPHIC INFORMATION (Tables)	6 Months Ended
	Jun. 30, 2014
Segment Reporting [Abstract]	'
Schedule of Segment Reporting Information, by Segment	'
	Segment information for the three months ended June 30, 2014 and 2013 is as follows:
		Dollars in Thousands
		Three Months Ended June 30, 2014
		Laboratory Services			Genetic Assays			Total
					and Platforms
	Net Sales	$	3,843		$	2,921		$	6,764
	Gross Profit	1,490			903			2,393
	Net Loss before Taxes	(3,277		)	(624		)	(3,901		)
	Income Tax Expense (Benefit)	40			(48		)	(8		)
	Net Loss	$	(3,317	)	$	(576	)	$	(3,893	)
	Depreciation/Amortization	$	438		$	50		$	488
	Interest Expense, net	$	83		$	63		$	146
		30-Jun-14
	Total Assets	$	23,370		$	7,721		$	31,091
		Dollars in Thousands
		Three Months Ended June 30, 2013
		Laboratory Services			Genetic Assays			Total
					and Platforms
	Net Sales	$	4,012		$	3,294		$	7,306
	Gross Profit	1,853			1,120			2,973
	Net Loss before Taxes	(2,181		)	(692		)	(2,873		)
	Income Tax Expense	—			(6		)	(6		)
	Net Loss	$	(2,181	)	$	(686	)	$	(2,867	)
	Depreciation/Amortization	$	646		$	41		$	687
	Interest Expense, net	$	84		$	67		$	151
		30-Jun-13
	Total Assets	$	27,834		$	11,529		$	39,363
	Segment information for the six months ended June 30, 2014 and 2013 is as follows:
		Dollars in Thousands
		Six Months Ended June 30, 2014
		Laboratory Services			Genetic Assays			Total
					and Platforms
	Net Sales	$	7,531		$	5,484		$	13,015
	Gross Profit	3,122			1,765			4,887
	Net Loss before Taxes	(6,261		)	(1,311		)	(7,572		)
	Income Tax Expense (Benefit)	549			(52		)	497
	Net Loss	$	(6,810	)	$	(1,259	)	$	(8,069	)
	Depreciation/Amortization	$	878		$	103		$	981
	Interest Expense, net	$	190		$	138		$	328
		Dollars in Thousands
		Six Months Ended June 30, 2013
		Laboratory Services			Genetic Assays			Total
					and Platforms
	Net Sales	$	8,439		$	6,241		$	14,680
	Gross Profit	4,046			2,182			6,228
	Net Loss before Taxes	(5,267		)	(1,127		)	(6,394		)
	Income Tax Expense (Benefit)	—			60			60
	Net Loss	$	(5,267	)	$	(1,187	)	$	(6,454	)
	Depreciation/Amortization	$	1,209		$	222		$	1,431
	Interest Expense, net	$	219		$	85		$	304
Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas	'
	Net sales for the three and six months ended June 30, 2014 and 2013 by country were as follows:
		Dollars in Thousands						Dollars in Thousands
		Three Months Ended June 30,						Six Months Ended June 30,
		2014			2013			2014			2013
	United States	$	4,870		$	5,797		$	9,633		$	11,146
	Italy	337			372			722			827
	All Other Countries	1,557			1,137			2,660			2,707
	Total	$	6,764		$	7,306		$	13,015		$	14,680

BUSINESS_DESCRIPTION_Details

BUSINESS DESCRIPTION (Details)	6 Months Ended
	Jun. 30, 2014
	operating_segments
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Number of operating segments	2

SUMMARY_OF_SIGNIFICANT_ACCOUNT3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Accounts Receivable (Details) (USD $)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Allowance for Doubtful Accounts Receivable [Roll Forward]	'	'	'	'
Beginning balance	$3,540	$2,549	$3,838	$2,171
Provision	850	608	1,523	2,197
Write-Offs	-349	-795	-1,320	-2,006
Ending balance	$4,041	$2,362	$4,041	$2,362
Accounts receivable, general payment terms1	'	'	'30 days	'
Accounts receivable, international extended payment terms greater than1	'	'	'90 days	'

SUMMARY_OF_SIGNIFICANT_ACCOUNT4

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Inventories (Details) (USD $)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Obsolete Inventory [Roll Forward]	'	'	'	'
Beginning balance	$849	$611	$799	$616
Provision	0	0	55	0
Write-Offs	-6	-18	-11	-23
Ending balance	$843	$593	$843	$593

SUMMARY_OF_SIGNIFICANT_ACCOUNT5

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Property, Plant and Equipment (Details) (USD $)	3 Months Ended		6 Months Ended
In Millions, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Property, Plant and Equipment [Line Items]	'	'	'	'
Depreciation expense	$0.10	$0.20	$0.20	$0.30
Depreciation expense, capital leases	$0.10	$0.10	'	$0.10
Leasehold improvements | Minimum	'	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'	'
Property and equipment, estimated useful lives	'	'	'1 year	'
Leasehold improvements | Maximum	'	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'	'
Property and equipment, estimated useful lives	'	'	'10 years	'
Furniture and fixtures | Minimum	'	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'	'
Property and equipment, estimated useful lives	'	'	'3 years	'
Furniture and fixtures | Maximum	'	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'	'
Property and equipment, estimated useful lives	'	'	'7 years	'
Production equipment | Minimum	'	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'	'
Property and equipment, estimated useful lives	'	'	'3 years	'
Production equipment | Maximum	'	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'	'
Property and equipment, estimated useful lives	'	'	'7 years	'
Computer equipment | Minimum	'	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'	'
Property and equipment, estimated useful lives	'	'	'3 years	'
Computer equipment | Maximum	'	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'	'
Property and equipment, estimated useful lives	'	'	'7 years	'
Research and development equipment | Minimum	'	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'	'
Property and equipment, estimated useful lives	'	'	'2 years	'
Research and development equipment | Maximum	'	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'	'
Property and equipment, estimated useful lives	'	'	'7 years	'

SUMMARY_OF_SIGNIFICANT_ACCOUNT6

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Accounting Policies (Details) (USD $)	0 Months Ended	3 Months Ended		6 Months Ended		12 Months Ended
	Jan. 27, 2014	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013	Dec. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'	'
Depreciation	'	$100,000	$200,000	$200,000	$300,000	'
Stock split, conversion ratio	0.0833	'	'	'	'	'
Common stock, par value (in dollars per share)	'	$0.01	'	$0.01	'	$0.01
Share-based compensation arrangement by share-based payment award, expiration period	'	'	'	'10 years	'	'
Unvested stock options, unrecognized compensation expense weighted average recognition period	'	'	'	'1 year 6 months	'	'
Stock-based compensation	'	'	'	637,000	162,000	'
Employee service share-based compensation, nonvested awards, total compensation cost not yet recognized, stock options	'	1,400,000	'	1,400,000	'	'
Stock options, granted	'	15,499	'	'	159,375	'
Stock options, fair value assumptions, risk free interest rate	'	1.74%	'	'	'	'
Stock options, fair value assumptions, dividend yield	'	0.00%	'	'	'	'
Stock options, fair value assumptions, expected life	'	'4 years 4 months 17 days	'	'	'	'
Stock options, fair value assumptions, historical volatility rate	'	83.00%	'	'	'	'
Common stock rights issued	'	'	'	115,065	691,656	'
Deferred revenue	'	1,212,000	'	1,212,000	'	1,088,000
Foreign currency translation adjustment, net of tax	'	22,000	0	34,000	-173,000	-45,000
Foreign currency transaction gain (loss), realized	'	'	'	-100,000	100,000	'
Options, warrants and conversion rights, common stock callable and antidilutive (in shares)	'	'	'	5,510,255	3,334,055	'
CEO	'	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'	'
Stock options, unvested options, vesting period	'	'	'	'3 years	'	'
Common stock rights issued	'	'	'	83,333	'	'
Share-based compensation arrangement by share-based payment award, fair value assumptions, exercise price	'	$4.32	'	$4.32	'	'
CFO	'	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'	'
Common stock rights issued	'	'	'	55,000	'	'
Pharmacogenomic services	'	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'	'
Deferred revenue	'	300,000	'	300,000	'	200,000
Diagnostic tools	'	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'	'
Deferred revenue	'	900,000	'	900,000	'	900,000
Additional Paid-in Capital (1) | Selling, General and Administrative Expenses [Member]	'	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'	'
Stock-based compensation	'	'	'	600,000	200,000	'
Accumulated Other Comprehensive Income	'	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'	'
Foreign currency translation adjustment, net of tax	'	'	'	$34,000	($200,000)	($45,000)
Minimum	'	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'	'
Stock options, unvested options, vesting period	'	'	'	'1 year	'	'
Maximum	'	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'	'
Stock options, unvested options, vesting period	'	'	'	'3 years	'	'

INVENTORIES_Details

INVENTORIES (Details) (USD $)	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Inventory Disclosure [Abstract]	'	'	'	'	'	'
Finished goods	$2,967	'	$2,978	'	'	'
Raw materials and work in process	1,663	'	1,567	'	'	'
Demonstration inventory	222	'	211	'	'	'
Inventory, gross	4,852	'	4,756	'	'	'
Less allowance for obsolescence	-843	-849	-799	-593	-611	-616
Inventories, net	$4,009	'	$3,957	'	'	'

INTANGIBLES_AND_OTHER_ASSETS_D

INTANGIBLES AND OTHER ASSETS (Details) (USD $)

3 Months Ended

6 Months Ended

6 Months Ended

12 Months Ended

6 Months Ended

6 Months Ended

6 Months Ended

6 Months Ended

6 Months Ended

6 Months Ended

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Dec. 31, 2013

Jun. 30, 2014

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Dec. 31, 2013

Service life

Acquired technology

Acquired technology

Acquired technology

Acquired technology

Assay royalties

Assay royalties

Third party payor relationships

Third party payor relationships

Tradenames and trademarks

Tradenames and trademarks

Customer relationships

Customer relationships

Covenants not to compete

Covenants not to compete

Patents

Patents

Intellectual property

Intellectual property

Minimum

Maximum

Acquired Finite-Lived Intangible Assets [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Finite-lived intangible assets, cost

$13,952,000

'

$13,952,000

'

$13,793,000

'

$9,009,000

$9,009,000

'

'

$1,434,000

$1,434,000

$367,000

$367,000

$824,000

$824,000

$652,000

$652,000

$184,000

$184,000

$1,216,000

$1,153,000

$266,000

$170,000

Finite-lived intangible assets, accumulated amortization

5,287,000

'

5,287,000

'

4,598,000

'

3,586,000

3,175,000

'

'

717,000

614,000

86,000

73,000

292,000

233,000

76,000

54,000

107,000

77,000

372,000

336,000

51,000

36,000

Finite-lived intangible assets, net book value

8,665,000

'

8,665,000

'

9,195,000

'

5,423,000

5,834,000

'

'

717,000

820,000

281,000

294,000

532,000

591,000

576,000

598,000

77,000

107,000

844,000

817,000

215,000

134,000

Finite-lived intangible asset, useful life

'

'

'

'

'

'

'10 years

'7 years

'7 years

'10 years

'7 years

'

'15 years

'

'7 years

'

'15 years

'

'3 years

'

'

'

'7 years

'

Amortization of intangible assets

300,000

500,000

700,000

900,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Amortization expense, 2014

1,400,000

'

1,400,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Amortization expense, 2015

1,400,000

'

1,400,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Amortization expense, 2016

1,300,000

'

1,300,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Amortization expense, 2017

1,300,000

'

1,300,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Amortization expense, 2018

1,000,000

'

1,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Income (loss) from continuing operations

'

'

'

'

'

100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net income (loss)

'

'

'

'

'

$100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Earnings per share, basic and diluted

($0.57)

[1]

($0.41)

[1]

($1.17)

($0.95)

'

$0.01

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

[1]

Net loss per share and the number of shares used in the per share calculations for all periods presented reflect the one-for-twelve reverse stock split that took effect on January 27, 2014.

DEBT_Details

DEBT (Details) (USD $)

Jun. 30, 2014

Dec. 31, 2013

Mar. 03, 2014

Jun. 30, 2014

Mar. 03, 2014

Mar. 02, 2014

Dec. 31, 2013

Mar. 03, 2014

Mar. 02, 2014

Mar. 13, 2013

Mar. 03, 2014

Jun. 30, 2014

Mar. 03, 2014

Dec. 31, 2013

Mar. 03, 2014

Mar. 03, 2014

Mar. 03, 2014

Mar. 13, 2013

Line of Credit

Line of Credit

Line of Credit

Line of Credit

Line of Credit

Line of Credit

Line of Credit

Line of Credit

Term Loan

Term Loan

Term Loan

Term Loan

Term Loan

Term Loan

Term Loan

Term Loan

Revolving Credit Facility

Revolving Credit Facility

Revolving Credit Facility

Revolving Credit Facility

Revolving Credit Facility

Revolving Credit Facility

Revolving Credit Facility

Revolving Credit Facility

Range One

Range Two

Range Three

Third Security LLC And Affiliates

Wall Street Journal Prime Rate

Wall Street Journal Prime Rate

Third Security LLC And Affiliates

Debt Instrument [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Total debt, including short term debt

$6,902,000

$6,560,000

'

$3,000,000

[1]

'

'

$2,560,000

[1]

'

'

'

'

$3,902,000

[2]

'

$4,000,000

[2]

'

'

'

'

Current maturities of long term debt

-691,000

-242,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Long-term debt, less current maturities

6,211,000

6,318,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Line of credit facility, current borrowing capacity

'

'

'

'

'

'

'

'

'

4,000,000

'

'

'

'

'

'

'

'

Debt instrument, face amount

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

4,000,000

Interest costs capitalized

'

'

'

'

'

'

'

'

'

'

'

100,000

'

'

'

'

'

'

Debt instrument, interest rate, stated percentage

'

'

'

'

6.25%

4.25%

'

'

'

'

'

'

'

'

'

'

'

'

Debt instrument, basis spread on variable rate

'

'

'

'

'

'

'

3.00%

1.00%

'

'

'

'

'

'

'

'

'

Debt instrument, interest rate, effective percentage

'

'

'

'

6.25%

'

'

'

'

'

'

'

'

'

'

'

'

'

Line of credit facility, upfront fee

'

'

20,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Line of credit facility, commitment fee amount

'

'

20,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Line of credit facility, unused capacity, commitment fee percentage

'

'

0.50%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Proceeds from issuance of long-term debt

'

'

'

'

'

'

'

'

'

'

4,000,000

'

'

'

'

'

'

'

Long-term debt, percentage bearing variable interest, percentage rate

'

'

'

'

'

'

'

'

'

'

'

'

9.10%

'

'

'

'

'

Debt instrument, upfront fee

'

'

'

'

'

'

'

'

'

'

40,000

'

'

'

'

'

'

'

Debt instrument, future debt extinguishment costs

'

'

'

'

'

'

'

'

'

'

$120,000

'

'

'

'

'

'

'

Debt instrument, prepayment penalty percent

'

'

'

'

'

'

'

'

'

'

'

'

'

'

5.00%

2.50%

1.00%

'

Debt instrument, debt default, interest rate, stated percentage increase

'

'

'

'

'

'

'

'

'

'

5.00%

'

'

'

'

'

'

'

[1]

Revolving Line of Credit. Amounts advanced under the Revolving Line bear interest at an annual rate equal to the greater of (a) 4.25% or (b) the Wall Street Journal prime rate plus 1%. Interest is payable on a monthly basis, with the balance payable at the maturity of the Revolving Line. Under the Amendment, amounts advanced under the Revolving Line bear interest at an annual rate equal to the greater of (x) 6.25% or (y) the Wall Street Journal prime rate plus 3%. The current interest rate is 6.25%. Under the Loan Agreement, we paid the Lenders an upfront fee of $20,000, and will pay the Lenders an additional commitment fee of $20,000 on each one year anniversary of the Effective Date during the term of the Revolving Line. In addition, a fee of 0.5% per annum is payable quarterly on the unused portion of the Revolving Line. The Revolving Line matures on September 1, 2016.

[2]

Term Loan. We received $4.0 million under the Term Loan on the Effective Date. Pursuant to the terms of the Loan Agreement, as amended by the Fourth Amendment, we are required to make monthly payments of principal and interest to the Lenders commencing on April 1, 2015. The current interest rate is 9.1%.We paid the Lenders an upfront fee of $40,000 for the Term Loan, and will pay the Lenders an additional final payment of $120,000 at maturity or prepayment of the Term Loan. In addition, if we repay the Term Loan prior to maturity, we will pay the Lenders a prepayment penalty of 5% of the total outstanding balance under the Term Loan if the prepayment occurs within one year after the Effective Date, 2.5% of the total outstanding balance under the Term Loan if the prepayment occurs between one and two years after the Effective Date, and 1% of the total outstanding balance under the Term Loan if the prepayment occurs thereafter.Additional TermsThe Loan Agreement contains affirmative and negative covenants. Under the Term Loan, we are required to maintain a minimum liquidity ratio and achieve a minimum amount of revenue, and we also agreed not to (i) pledge or otherwise encumber our assets other than to the Lenders, (ii) enter into additional borrowings or guarantees, (iii) repurchase our capital stock, or (iv) enter into certain mergers or acquisitions without the Lenders’ consent. Additionally, the Loan Agreement contains a subjective acceleration clause at the discretion of the Lenders. As of June 30, 2014, we were in compliance with all financial covenants.To secure the repayment of any amounts borrowed under the Revolving Line and the Term Loan, we granted the Lenders a security interest in all of our assets. The occurrence of an event of default under the Loan Agreement could result in the acceleration of our obligations under the Loan Agreement and would increase the applicable interest rate under the Revolving Line or Term Loan (or both) by 5%, and permit the Lenders to exercise remedies with respect to the collateral under the Loan Agreement.

COMMITMENTS_AND_CONTINGENCIES_

COMMITMENTS AND CONTINGENCIES (Details) (USD $)	6 Months Ended
In Millions, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013
Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]	'	'
Operating leases, future minimum payments due, next twelve months	$0.60	'
Operating leases, future minimum payments due, 2015	1	'
Operating leases, future minimum payments due, 2016	0.9	'
Operating leases, future minimum payments due, 2017	0.8	'
Operating leases, future minimum payments due, 2018	0.5	'
Operating leases, future minimum payments, due thereafter	0.9	'
Operating leases, rent expense	0.5	0.6
Firm commitments to vendors	$1.30	'

INCOME_TAXES_Details

INCOME TAXES (Details) (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Income Tax Disclosure [Abstract]	'	'	'	'
INCOME TAX (BENEFIT) EXPENSE	($8,000)	($6,000)	$497,000	$60,000
Effective income tax rate, continuing operations	'	'	6.57%	'
Effective tax rate reconciliation, permanent differences, goodwill amortization	'	'	500,000	'
Effective income tax rate reconciliation, prior year income taxes, amount	'	'	$400,000	'

STOCKHOLDERS_EQUITY_Details

STOCKHOLDERS' EQUITY (Details) (USD $)

0 Months Ended

1 Months Ended

6 Months Ended

12 Months Ended

0 Months Ended

0 Months Ended

Feb. 02, 2012

Dec. 31, 2011

Jan. 24, 2013

Jun. 30, 2014

Jun. 30, 2013

Dec. 31, 2013

23-May-12

Feb. 02, 2012

Dec. 31, 2010

Feb. 02, 2012

Feb. 02, 2012

Mar. 13, 2013

Mar. 13, 2013

Dec. 31, 2013

Mar. 05, 2014

Dec. 31, 2013

Mar. 05, 2014

Mar. 05, 2014

Third Security LLC And Affiliates

Affiliates of third security, llc; december twenty-fifth 2010

Various institutional holders; february seventh, 2012

Affiliates of third security, llc; february seventh, 2012

Various institutional holders; january twenty-fourth, 2017

Affiliates of third security, llc; january twenty-fourth, 2017

Maximum

Maximum

Minimum

Minimum

Series B Preferred Stock

Third Security LLC And Affiliates

Third Security LLC And Affiliates

Preferred Stock

Third Security LLC And Affiliates

Class of Stock [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock, shares authorized

'

'

'

150,000,000

'

150,000,000

150,000,000

'

'

'

'

'

'

'

'

'

'

'

Proceeds from issuance of common stock and convertible notes

$22,000,000

$3,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock, shares issued

1,583,333

'

'

7,353,695

'

7,353,695

'

'

'

'

'

'

'

'

'

'

'

'

Common stock, sale price per share (in dollars per share)

$12

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock warrants, term

'5 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock warrant, common stock called

823,333

'

691,656

2,335,348

'

'

'

'

431,027

[1]

1,052,820

[2]

'

441,656

[3]

250,000

[3]

1,097,600

1,212,665

948,333

1,097,600

'

Common stock warrant, exercise price

15

'

'

'

'

'

'

'

6.96

[1]

11.73

[2]

11.73

[2]

9

[3]

9

[3]

15

12.96

12.96

11.73

'

Convertible notes, common stock callable

'

'

'

'

'

'

'

250,000

'

'

'

'

'

'

'

'

'

'

Convertible notes, warrants callable

'

'

'

'

'

'

'

125,000

'

'

159,845

[2]

'

'

'

'

'

'

'

Payments of stock issuance costs

1,330,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Payments of stock issuance costs, percentage of gross offering proceeds

7.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Payments of stock issuance costs, warrant right to purchase common stock shares

31,666

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Payments of stock issuance costs, warrant right to purchase common stock shares, percentage of shares in offering

2.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock issuance costs, reimbursable expenses

125,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Payments of stock issuance costs, reduction to equity

1,500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Private Placement, net, shares

'

'

1,383,333

'

'

'

'

'

'

'

'

'

500,000

'

'

'

'

1,443,297

Share price

'

'

$6

$3.74

'

'

'

'

'

'

'

'

'

'

'

'

'

$4.85

Private placement, net

'

'

$8,300,000

'

'

$7,570,000

'

'

'

'

'

'

'

'

'

'

'

$7,000,000

Class of warrant or right, number of securities called by warrants or rights, price per share

'

'

$9

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock warrants issued

'

'

'

115,065

691,656

'

'

'

'

'

'

'

'

'

'

'

'

'

Preferred stock, par value (in dollars per share)

'

'

'

$0.01

'

$0.01

'

'

'

'

'

'

'

'

'

'

'

$0.01

[1]

This warrant was issued in connection with the issuance of warrants to purchase shares of our Series A Preferred Stock to affiliates of Third Security, LLC in December 2010. The number of underlying shares shown reflects the number of shares of common stock issuable upon conversion of the shares of Series A Preferred Stock for which this warrant is currently exercisable.

[2]

These warrants were issued in connection with the Private Placement completed in February 2012 and are classified as a liability in our financial statements. See Footnote 9 - Fair Value. These warrants also contain certain anti-dilution provisions that provide for an adjustment to the exercise price and number of shares issuable upon exercise of the warrant in the event that we engage in certain issuances of shares of our common stock at a price lower than the exercise price of the warrant.

[3]

These warrants were issued in connection with the Offering, which was completed in January 2013.

FAIR_VALUE_Details

FAIR VALUE (Details) (USD $)	6 Months Ended			3 Months Ended		6 Months Ended
In Thousands, except Share data, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jan. 24, 2013	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
				Liability	Liability	Liability	Liability
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]	'	'	'	'	'	'	'
Common stock warrants issued	115,065	691,656	'	'	'	1,200,000	'
Share price	$3.74	'	$6	'	'	'	'
Stock options, fair value assumptions, expected life	'2 years 7 months 10 days	'	'	'	'	'	'
Volatility	55.00%	'	'	'	'	'	'
Risk-free interest rate	0.68%	'	'	'	'	'	'
Fair value assumptions, expected term	'2 years 6 months	'	'	'	'	'	'
Percentage of simulated equity values below the down-round financing cut-off point	25.00%	'	'	'	'	'	'
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]	'	'	'	'	'	'	'
Beginning balance	'	'	'	$550	$500	$600	$900
Total gains or losses	'	'	'	'	'	'	'
Recognized in earnings	'	'	'	-200	-200	-250	-600
Ending balance	'	'	'	$350	$300	$350	$300

STOCK_OPTIONS_Details

STOCK OPTIONS (Details) (USD $)	3 Months Ended	6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2014	Jun. 30, 2014	Dec. 31, 2013
			Equity incentive plan 2006	Employee stock option	Stock appreciation rights (SARs)	Stock appreciation rights (SARs)
Number of Options [Rollforward]	'	'	'	'	'	'
Balance at January 1, 2014	'	'	'	565,028	'	'
Granted	15,499	159,375	214,296	214,296	'	'
Forfeited	'	'	'	-47,559	'	'
Expired	'	'	'	-545	'	'
Balance at June 30, 2014	731,220	'	'	731,220	'	'
Exercisable at June 30, 2014	'	'	'	194,663	'	'
Weighted Average Exercise Price [Roll Forward]	'	'	'	'	'	'
Balance at January 1, 2014	'	'	'	$7.19	'	'
Granted	'	'	$5.47	$5.47	'	'
Forfeited	'	'	'	$5.07	'	'
Expired	'	'	'	$14.28	'	'
Balance at June 30, 2014	'	'	'	$6.82	'	'
Exercisable at June 30, 2014	'	'	'	$11.03	'	'
Number of Options	'	'	'	'	'	'
Number of Options, beginning balance	'	'	'	'	138,333	138,333
Number of Options, ending balance	'	'	'	'	138,333	138,333
Number of Options, exercisable	'	'	'	'	0	'
Weighted-Average Exercise Price	'	'	'	'	'	'
Weighted-Average Exercise Price, beginning balance	'	'	'	'	$4.32	$4.32
Weighted-Average Exercise Price, ending balance	'	'	'	'	$4.32	$4.32
Weighted-Average Exercise Price, exercisable	'	'	'	'	$0	'

OPERATING_SEGMENT_AND_GEOGRAPH2

OPERATING SEGMENT AND GEOGRAPHIC INFORMATION (Details) (USD $)	3 Months Ended		6 Months Ended		12 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013	Dec. 31, 2013
			operating_segments
Segment Reporting Information [Line Items]	'	'	'	'	'
Number of operating segments (in operating segments)	'	'	2	'	'
Net Sales	$6,764	$7,306	$13,015	$14,680	'
Gross Profit	2,393	2,973	4,887	6,228	'
Net Loss before Taxes	-3,901	-2,873	-7,572	-6,394	'
Income Tax Expense (Benefit)	-8	-6	497	60	'
Net Loss	-3,893	-2,867	-8,069	-6,454	-15,987
Depreciation/Amortization	488	687	981	1,431	'
Interest expense, net	146	151	328	304	'
Total Assets	31,091	39,363	31,091	39,363	30,278
Laboratory services	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'
Net Sales	3,843	4,012	7,531	8,439	'
Gross Profit	1,490	1,853	3,122	4,046	'
Net Loss before Taxes	-3,277	-2,181	-6,261	-5,267	'
Income Tax Expense (Benefit)	40	0	549	0	'
Net Loss	-3,317	-2,181	-6,810	-5,267	'
Depreciation/Amortization	438	646	878	1,209	'
Interest expense, net	83	84	190	219	'
Total Assets	23,370	27,834	23,370	27,834	'
Genetic Assays and Platforms [Member]	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'
Net Sales	2,921	3,294	5,484	6,241	'
Gross Profit	903	1,120	1,765	2,182	'
Net Loss before Taxes	-624	-692	-1,311	-1,127	'
Income Tax Expense (Benefit)	-48	-6	-52	60	'
Net Loss	-576	-686	-1,259	-1,187	'
Depreciation/Amortization	50	41	103	222	'
Interest expense, net	63	67	138	85	'
Total Assets	7,721	11,529	7,721	11,529	'
United states	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'
Net Sales	4,870	5,797	9,633	11,146	'
Italy	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'
Net Sales	337	372	722	827	'
All Other Countries [Member]	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'
Net Sales	$1,557	$1,137	$2,660	$2,707	'
Maximum | All Other Countries [Member]	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'
Percent of revenue from countries not separately disclosed	'	'	5.00%	'	'
Minimum | United states	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'
Long-lived asset percentage held in a specific location	99.00%	'	99.00%	'	'

SUBSEQUENT_EVENTS_Details

SUBSEQUENT EVENTS (Details) (Subsequent Event [Member], Surveyor Kit Patent, Technology and Inventory Purchase Agreement [Member], USD $)	0 Months Ended
In Millions, unless otherwise specified	Jul. 01, 2014
	Installment
Subsequent Event [Member] | Surveyor Kit Patent, Technology and Inventory Purchase Agreement [Member]	'
Subsequent Event [Line Items]	'
Proceeds from Sales of Business, Affiliate and Productive Assets	$3.65
Additional Expected Proceeds from Sales of Business, Affiliate and Productive Assets	$0.60
Number of Additional Expected Proceed Installments	4